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Chordomas are rare, low-to-intermediate grade malignant tumors arising from notochordal
remnants in the midline skeletal axis. They account for <1% of central nervous system tumors
and <5% of all primary malignant bone tumors. It is characterized by slow growth, local
recurrence, and low metastasis rates. An increasing variety of techniques is now available to
detect genetic alterations in chordomas, herein, we review the current knowledge of the
genetic alterations in the skull base chordomas. The distribution of copy number changes is
composed by two approaches; the low-resolution banding karyotyping and high-resolution
whole genome CGH approach. The mapping of candidate genes in chordoma genesis
awaits the application of high resolution targeted approaches. Chromosome 1p36.13 and
7q33 represent a candidate region for a chordoma gene. In gene expression study, many
genes, such as HER2/neu, epidermal growth factor receptor, c-Met, platelet-derived growth
factor receptor A and B, KIT receptors, E-cadherin, neural cell adhesion molecule,
progesterone receptor B, estrogen receptor alpha, transforming growth factor alpha and
basic fibroblast growth factor, fibronectin, and Cathepsin K, are differentially expressed and
act a potential therapeutic target.
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▒ Introduction
Chordomas are rare, low-to-intermediate grade malignant
tumors arising from notochordal remnants in the midline
skeletal axis. They account for <1% of central nervous system
tumors 1) and <5% of all primary malignant bone tumors. 2)
Clinically they are slow-growing tumor characterized by local
spread. Symptoms manifest late, even after years, and
therefore the local extent of disease is often huge at
diagnosis. The natural course of chordoma is quite grim;
most patients do not survive 10 years because of high
recurrence rates.3, 4) Given the natural history and high local
recurrence rates, treatment is based on local modalities. The
current treatment of choice is aggressive surgical excision
followed by local irradiation, but even with the best
treatments available, overall survival time remains roughly 5
years.5)
Given the rare nature of these tumors, relatively little is
known about the molecular biology. With the recent
introduction of targeted molecular therapeutics into clinical
practice, an enhanced understanding of the molecular biology
of chordomas is needed. An increasing variety of techniques
is now available to detect genetic alterations in chordomas,
including immunohistochemistry for the detection of products
of altered gene expression, karyotype analysis, fluorescence
in situ hybridization (FISH) of chromosome spreads to assess
ploidy status and identify certain genetic rearrangements,
Southern blotting and the polymerase chain reaction (PCR)
for genomic DNA analysis, reverse transcriptase polymerase
chain mRNA products, and DNA sequencing. 
Herein, we review the current knowledge of the genetic
alterations in the skull base chordomas.
▒ Histopathology and Immunohistochemistry
Grossly, chordomas are multilobulated, gray, partially
translucent, glistening, cystic or solid masses that resemble
cartilage tumors or occasionally a mucin producing
carcinoma. Microscopically, the tumor is characterized by a
distinct, lobular architecture that is formed by the
physaliphorous (‘soap bubble’) cells with ample vacuolated
cytoplasm as well as by the ‘signet ring’type; in between the
cells, there are fibrous septae which are incomplete and
densely infiltrated by lymphocytes. Chordomas are of three
overlapping, chondroid and dedifferentiated. To the areas
showing physaliphorous cells, an occasional tumor may show
a typical spindle cell sarcoma arrangement or a round ell
pattern, while others may show an epithelial arrangement.
Following treatment with radiation therapy, areas of spindle
cell sarcoma formation may be seen. 
Differential diagnosis of chordomas includes primary bone
tumors, cartilagineous neoplasms such as chondromas or
chondrosarcomas, epithelial neoplasms such as mucinous-
forming adenocarcinoma or salivary neoplasms, metstases,
neurinoma, neurofibroma, meningioma, neuroblastoma,
hemangioma and lymphoma. Chordomas are usually positive
for keratin and S-100 protein and can be differentiated from
epithelial neoplasms. 6, 7) Cartilage tumors and keratin
negative and adenocarcinomas are S-100 negative.
Cytokeratin antibodies and EMA (epithelial membrane
antigen) positivity of chordoma is used to distinguish it from
cartilaginous neoplasms, where the absence of these
epithelial markers should be the rule. 8) Immunoperixidase
staining is useful in distinguishing chordoma from
adenocarcinoma and cartilage tumors. Some chordomas stain
positive with vimentin antisera, which reflects mesenchymal
differentiation.9) 
▒ Cytogenetics, FISH and CGH
The cytogenetic description by conventional banding and
FISH-based techniques is restricted to less than 100 cases of
chordoma worldwide. Persons et al.10) recorded twenty-nine
cases of conventional chordoma with aberrant karyotype in
the Mitelman Catalog of Chromosome Aberrations in Cancer
(CGAP). Six additional tumors, recently published, can be
added to this list. 11, 12) Out of 35 chordomas with aberrant
karyotype, 18 are annotated as recurrences: two as
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metastases, four as primary tumors, while no information is
available for the remaining 11 tumors. The high rate of
recurrent tumors among chordomas with aberrant karyotype
is in keeping with the suggestion that in chordomas
chromosome aberrations appear as late events in tumor
progression.13) The great majority are either hypo or quasi-
diploid and only two are hyperdiploid.13, 14) Only a few cases
have simple karyotypes with one or more aberrations, but no
underlying breakpoint was shared among chordomas
characterized by a sole balanced translocation or
rearrangement.13, 15-18) So far there are no clues that specific
translocations, resulting in chimeric genes, play a
pathogenetic role in chordomas. As to numerical chromosome
abnormalities, losses involve in the order chromosomes 3, 13,
10, 22, 4, 18, 14, 9 and Y, while gains affect preferentially
chromosomes 7, 2 and 21 [CGAP]. Imbalances of chromosome
arms or subchromosomal regions were also identified, most
commonly loss of 3p, 3q or both segments, loss of 1p and 9q,
but in most cases these were gross alterations, and their
pattern appears to be not specific [CGAP]. A large variety of
rearrangements, among which isochromosome 1q and loss of
part or all of 1p were identified as equivalent recurrent
changes associated with chordoma progression. 13, 19) Loss of
1pter-p34 has been detected in 14 cases,11) suggesting that a
tumor suppressor locus might map in 1p36.20) CGH analysis
evidenced copy number changes restricted to chromosome
arms or smaller genomic regions, but due to the limited
number of tumor samples, only a few generalities can be
drawn. One, at apparent discordance with karyotype data, is
that gains were more common than losses. One third of the
tumors analyzed by CGH combined to FISH were
hyperdiploid: a finding making the authors suggest that hypo
or near diploid cell populations have a growth advantage in
vitro.21) Hypodiploidy is not a feature of human solid tumors.
More precisely, the investigation of 16 chordomas showed
that there was a median of six chromosomal imbalances per
tumor, on average, 3.2 losses and 4.2 gains. Most common
losses mapped on chromosomal arms 3p (50%) and 1p (44%)
and most common gains involved 7q (69%), 20 (50%), 5q (38%)
and 12q (38%). 21) Another study disclosed that the most
frequently observed chromosomal imbalances were gains in
chromosomes 1q, 7p, 7q, and 19q and loss in chromosome
9p.24) The consensus region for gains on chromosome 7q was
7q36, where the homeobax gene HLXB9 and sonic hedgehog
gene SHH reside: interestingly both genes are a plausible
candidate as they are expressed throughout the notochord
during embryogenesis. 22) Use of high resolution FISH
techniques, such as COBRA did not pinpoint any clustering of
breakpoints, but confirmed loss of chromosome arms 1p, 3p,
3q, 9p and chromosome 10.11) Gains and losses are indicated
by lines to the right and to the left of each chromosome
ideogram. The distribution of copy number changes is
composed by two approaches; the low-resolution banding
karyotyping and high-resolution whole genome CGH
approach. The mapping of candidate genes in chordoma
genesis awaits the application of high resolution targeted
approaches. 
▒ LOH and Microsatellite studies
The first LOH study on chordomas concerned the Rb locus
(13q14) at which LOH was detected in two of 7
sphenooccpital/clivus tumors, and proposed by correlation
with the clinical behavior as a marker of aggressive tumors.23)
Further LOH studies evidenced the loss of 17p, 9p and 18q,
where known tumor suppressor genes are mapped.25) It has
been reported that the combined loss of p53 function and RB1
protein leads to genomic instability, a finding consistent with
the model of progressive accumulation of genetic changes
with increasing malignancy.26)
Riva and colleagues’research with 28 chordoma specimens
suggests that the possible importance of the short arm of
chromosome 1.27) The 1p36.13 band had been pinpointed by
the recurrent breakpoints identified in two tumor recurrences
of the founder of an Italian chordoma family and the
haplotype and LOH information retrieved on this family. 19, 20)
Typing of 31 region-specific microsatellites evidenced LOH
across 1p36.13 in 25 out of 27 sporadic chordomas.27, 34) The
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first selection of region-specific genes was based on genes
with functions-related to development or regression of the
notochord such as Caspase 9 (CASP9) and Ephrin 2A
(EPH2A). CASP9 is a ubiquitously expressed protease which
triggers the apoptotic pathway by releasing cytochrome c
from mitochondria and the cytosol. 28) EPH2A is a tyrosine
kinase receptor involved in tail notochord formation during
mouse embryo development. 29) Additional candidate genes
come to the attention when a wider LOH region, which is
shared by a lower percentage (40%) of chordomas is
considered. They include the paired box 7 (PAX7) gene
encoding a transcriptional factor expressed in the neural tube
which is regulated by notochord specific signals, 30) the
differentially screening-selected gene aberrant in
neuroblastoma (DAN), involved in the negative regulation of
cell proliferatin,31) the Dishevelled 1 gene (DVL1), a key factor
in Wnt signaling expressed in the neural tube29) and a few
genes belonging to the tumor necrosis factor receptor
superfamily (TNFRSF-1B, -8, -9, -14), the DNA
fragmentation factor (DFF-A and -B). Priliminary RT-PCR
expression analysis of eight chordomas evidenced the lack of
CASP9, EPHA2 and DVL1 transcripts in 5, 1, and 4 tumors,
respectively. In recent study, tumor necrosis factor receptor
superfamily genes were differently expressed compared with
control in a higher percentage of tumors (40-53%),
suggesting that the deregulation of these three genes might
have a role in chordoma tumorigenesis. 34) Kelly and
colleagues performed a genomic linkage analysis on families
with multiple members who had chordomas and were able to
isolate a locus on chromosome 7q33.32) The absence of LOH
may indicate that the disease gene exerts its oncogenic effect
in a dominant way. 
▒ Gene expression study
Weinberger et al. 33) evaluated the specimens from ten
patients for HER2/neu, epidermal growth receptor (EGFR)
and c-Met expression. They found that HER2/neu expression
was seen in 70% of cases, EGFR in 100% and c-Met in 100%;
expression of c-Met and EGFR were correlated. Tamborini et
al.35) studied 31 cases of sacral, spinal or clival chordomas for
expression of platelet-derived growth factor receptor (PDGF
receptor) A and B and KIT receptors. PDGFB receptor
expression and phosphorylation and the presence of PDGFB
were seen in the samples analyzed, suggesting an
autocrine/paracrine loop as a possible mechanism
contributing to the pathogenesis of chordomas; similar
findings were observed for PDGFA and KIT receptors but at
lower expression levels. Mori et al.36) reviewed seven cases of
chordoma for the expression of E-cadherin, which was
expressed in all chordomas cells, especially at intracellular
adhesion sites, but epithelial cell adhesion molecule was not
consistently expressed. 
The expression of cell adhesion molecules (CAMs) including
E-cadherin, alpha-catenin, beta-catenin, gamma-catenin
and neural cell adhesion molecule (NCAM) has been
associated with formation and maintenance of chordoma
tissue architecture and found a diagnostic value for
discriminating chordoma from chondrosarcoma.39) Saad et
al.37) reviewed eight cases of pediatric chordomas and found a
negative correlation between the percentage of cells
expressing E-cadherin and tumor recurrence and survival; a
similar finding was seen for the MIB-1 labeling index but
they note that this observation differs from adult patients
where the MIB-1 labeling index is much lower. Palini et al.38)
found that there was an association with p53 mutations and
expression of human telomerase reverse transcriptase mRNA
and the combination was predictive of aggressive tumor
behavior. 
Investigations on steroid hormone receptors, which are
involved in tumor growth, evidenced that progesterone
receptor B and estrogen receptor alpha were expressed in
chordoma and hence associated with tumor progression.40)
High levels of transforming growth factor alpha and basic
fibroblast growth factor expression were linked to higher
rates of recurrence and strong fibronectin expression was
also associated with poor prognosis, being thus considered an
additional marker of aggressiveness. 41) Cathepsin K is a
member of the papain family of cystine protease and is
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considered to play an important role in osteoclast resorption.
This protein was localized to the advancing tumor front in 44
specimens of chordoma using immunohistochemistry and
RT-PCR.42) This data indicates Cathepsin K as an important
mediator of proteolytic degradation in chordoma spread, and
a potential therapeutic target to reduce tumor spread and
recurrence.
▒ Conclusions
Chordomas is a peculiar tumor and is characterized by slow
growth, local recurrence, and low metastasis rates. Given the
rare nature of these tumors, relatively little is known about
the molecular biology. An increasing variety of techniques is
now available to detect genetic alterations in chordomas,
including immunohistochemistry for the detection of products
of altered gene expression, karyotype analysis, fluorescence
in situ hybridization (FISH) of chromosome spreads to assess
ploidy status and identify certain genetic rearrangements,
Southern blotting and the polymerase chain reaction (PCR)
for genomic DNA analysis, reverse transcriptase polymerase
chain mRNA products, and DNA sequencing. Potential
candidate genes should thus emerge, besides residing in
genomic intervals, such as 1p36 and 7q33, which are though
to be relevant for chordoma tumorigenesis and/or
progression. In addition, microsatellite instability and  LOH of
the candidate genes is strongly involved in chordoma
tumorigenesis and/or progression. In gene expression study,
many genes, such as HER2/neu, EGFR, c-Met, PDGF
receptor A and B, KIT receptors, E-cadherin, NCAM,
progesterone receptor B, estrogen receptor alpha,
transforming growth factor alpha and basic fibroblast growth
factor, fibronectin, and Cathepsin K, are differentially
expressed and act a potential therapeutic target. Further
studies are warranted for understanding of molecular biology
and targeted molecular therapeutics of skull base chordoma.
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Management strategy of large vestibular schwannomas (VS) is still on debate regarding
complete removal for tumor control versus incomplete removal for cranial nerve preservation.
Still surgery for VS is difficult task for most neurosurgeons to achieve good tumor control rate
without neurological sequela. Introduction of radiosurgery has greatly changed therapeutic
strategies for large VS, but it has limitations due to large tumor mass. Admist the on-going
controversy over optimal therapeutic strategy for large VS, we reviewed literatures for recent
trends of therapeutic strategy for large VS.
Near-total removal (NTR) and radical sub-total removal (R-STR) followed by radiosurgery
showed comparable tumor control rate and favorable facial nerve preservation rate. If
preservation of facial nerve is guaranteed, NTR alone is recommended. In case of
incomplete surgical resection to save facial nerve integrity, adjuvant radiosurgery is beneficial
for tumor control.
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▒ 크기가큰청신경초종치료의역사적고찰
청신경초종의첫성공적인수술은1894년Balance에의해이루
어졌다.2) 우측소뇌다리뇌각(cerebellopontine angle)에있는, 경계
가좋은종양을제거하였으며, 수술시행12년후환자가생존해있
음을보고하였다. 1917년Cushing은청신경초종의종양의피막내
부분절제의성공적시행을보고하였으며,5) 1925년 Dandy에이르
러 종양의 완전 제거를 통한 수술적 완치를 보고하였다.6) 1949년
Olivecrona가안면신경을보존하면서청신경초종수술에성공하였
으며, 17) 1968년 House는 미로경유접근법(translabyrinthine
approach)를청신경초종수술에성공적으로재적용하였다.9) 처음
Leksell이 1969년에청신경초종에대한방사선치료를시도하였으
며,16) 1974년Yasargil에의해현미경을이용한수술법이소개되었
다.29) 신경외과수술의마취에대한이해향상및유발전위를이용
한 안면신경에 대한 수술 중 감시 방법이 소개되면서, 1995년
Jannetta는 큰 청신경 초종의 치료에서의 단계적 수술법 (staged
operation)의개념을제시하였다.4)
▒ 크기에따른청신경초종의분류와증상의변화
일반적으로직경 1.5cm 미만의경우“small size”, 1.5에서 3cm
사이를 ”medium size”, 3cm 이상을“large size”로 분류하며,
“large size”로분류된종양중4cm 이상의경우“giant”, 5cm 이상
의경우에는“huge”로분류한다.
증상의정도에따라병기 (stage)를나누고있으며, 청력의변화,
전정신경장애에의한증상이나타나는경우를병기 I, 여기에삼차
신경장애및매우드물지만안면신경장애의한증상이동반되는
경우병기II, 하부뇌신경장애및뇌간, 소뇌장애에의한증상이추
가로동반되는경우를병기 III, 상기증상에수두증에의한증상이
추가로동반되는경우병기IV로분류하고있다(Table 1).
종양의크기는병기와직접적인연관성이있다. 일반적으로청신
경초종은크기가클수록그증상의정도가심해지며, 큰청신경초
종의경우, 소뇌와뇌간을압박하여증상을유발하며, 안과적장애
를 포함하는수두증에의한증상들이발현할 가능성이있다. 수술
중에주변중요조직들과심하게유착이되어있는경우가많아수
술이어렵고, 수술후발생하는청력소실은대부분호전되기어려
우며, 안면신경및하부뇌신경장애를포함한주요합병증이발생할
가능성이높다.20)
따라서, 큰 크기의 청신경 초종을 치료함에 있어 종양 억제
(tumor control)와더불어안면신경및하부뇌신경의기능보존에
상당한주의가필요하다.
▒ 과거의치료성적및최근치료경향
청신경 초종의 수술 후 재발률은 완전절제 (gross total
resection, GTR)를시행하였을경우대략10% 내외로보고되고있
으며 (Table 2),3, 8, 22, 26) 아전절제 (subtotal resection, STR)을시행
하였을경우25~32%의재발률이보고되고있다(Table 3).1, 12, 24)
큰크기의청신경초종(large size 이상)의수술후안면신경마비
Small < 1.5 cm I < 1 cm I CN VIII only †
Medium 1.5-3 cm II 1-2 cm II + CN V or VII ‡
III 2-3 cm III + BS, Low CN, Cbll §
Large* > 3 cm IV > 3 cm IV + IICP ¶
Size Grade Stage Symptom
(Koos, 1985) (CPA syndrome)
Table 1. Classification of vestibular schwannomas according
to its size and symptoms Size and symptoms
* Giant: > 4cm, Huge: > 5cm
† Auditory & vestibular dysfunction
‡ Stage I + facial motor or sensory dysfunction
§Stage II + low cranial nerve or cerebellar dysfunction or   
brainstem compression signs
¶ Stage III + symptoms of hydrocephalus
Abbreviation: CPA, cerebellopontine angle; CN, cranial nerve; BS,
brain stem; Cbll, cerebellum; IICP, increased intracranial pressure
Acoustic Neuroma Registry 26) 1579 8%
Samii et al 22) 1000 0.7%
Cerullo et al 3) 55 9%
Mazzoni et al 104 8%
Gormley et al 8) 178 < 1%
N Recurrence
Table 2. Reported recurrence rate after gross-total resection
of vestibular schwannoma
Bloch et al 1) 52 5 NTR 3%
R-STR 32%
Sakaki et al 24) 29 10 R-STR 25%
Kameyama 12) 19 10 R-STR 26%
N F/U(years) Extent of removal Recurrence
Table 3. Reported recurrence rate after incomplete resection
of vestibular schwannoma
Abbreviation: F/U, follow up; NTR, near-total resection; R-STR,
radical sub-total resection
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정도는Yasargil 등이37%, King & Morrison 등이80%, House &
Hitselberger 등이40%, Ebersold 등이24%로보고하고있어술자
에따라그정도가매우다양하다(Table 4).7, 10, 13, 15, 23, 30)
최근들어수술기법의발전과수술중감시기법의발전, 그리고
방사선수술의발전으로큰크기의청신경초종을치료하는데있어
수술을통한부분적절제후남은종양에대한방사선수술을시행
하는단계적치료전략이제시되었다. 크기가큰청신경초종을안
면신경의손상없이완전히제거하는것은외과의의상당한경험이
요구되며, 그정도의숙련도를가진신경외과의는소수라는점, 최
근 방사선수술의대중화로청신경초종수술건수가감소추세에
있어, 수술을경험하기가예전보다더어려워졌다는현실이이전략
의타당성을뒷받침한다. 또한, Iwai 등과 Prasad 등은 크기가큰
청신경초종을아전절제후방사선수술을시행하였을때, 완전절제
를시행하였을때의종양억제정도와비슷한90% 이상의성적을보
여주고있으며, 안면신경마비의빈도도15% 이하로현저히낮음을
보고한바있어 (표 5),11, 19) 최근에는크기가큰청신경초종의치료
에있어수술적제거후방사선수술을시행하는단계적치료전략
이많이채택되고있다.25)
그러나, 아직 방사선수술합병증의생물학적발생기전에대한
이해가불확실하고, 치료효과에대한큰규모의연구도없는데다, 8
년이상의장기간추적관찰한연구자료는거의없는실정이어서,
아직수술적으로완전제거하는치료전략과의우위를비교하기는
이르다. 종양을아전절제해야하는상황및정도에대한기준이모
호하며, 수술을진행함에있어수술중전기생리학적인감시장치만
으로도안면신경기능을충분히보존할수있다는주장도있어, 아직
크기가큰청신경초종의치료전략에대한논의는아직진행중이
다.25, 27, 28) 
환자의나이, 기대수명, 종양의크기와주변조직과의유착정도,
환자의전신상태, 수술후합병증이환률, 그리고환자본인의선호
도등의다양한변수가치료전략에영향을미친다. 이글에서는서
울대병원에서치료한크기가큰청신경초종의최근치료경험을분
석한연구결과의고찰을통해, 치료전략에대한최근의경향을소
개하고자한다.
▒ 서울대병원에서의크기가큰
청신경초종치료결과분석및고찰18)
연구대상및방법
1990년부터1999년까지10년동안3cm 이상의청신경초종으로
수술 받은 환자를 대상으로 후향적 분석 (retrospective analysis)
을시행하였다. 모두한명의신경외과의(HWJ)에게수술받은환자
들로, 신경섬유종증 2형 (neurofibromatosis type II)과 단계적수
술 (staged surgical operation)을계획, 시행하였던환자는제외하
였다. 총50명의환자가연구에포함되었으며, 평균경과관찰기간
은113 개월(58-167 개월)이었다.
종양의성상
종양의평균지름은36.4mm (30.0-47.2 mm)이었고, 평균부피
는 26.8cc (13.5-55.1 cc)였다. 환자의 40%가 고형 종양 (solid
tumor)였으며, 고형성 병변에 낭성 병변이 섞여 있는 종양 (solid
and cystic tumor) 이 52%, 그리고낭성병변만있는종양을가지
고있는환자가8%였다.
Yasargil (1977)30) > 3.0 37%
King & Morrison (1980)13) > 2.5 80%
House & Hitselberger (1985)10) > 4.0 40%
Samii (1985)23) > 3.0 46%
Ebersold (1992)7) > 4.0 24%
Lanman (1999)15) > 3.0 47.4%
Tumor size (cm)  Facial nerve palsy
Table 4. Functional preservation after surgery of large
vestibular schwannoma
Iwai et al11) 14 42mm 3 93% 14.3%
Prasad et al19) 57 UM 10 90% 11%
N Size F/U(years) Tumor control rate FNP
Table 5. Reported outcomes after incomplete resection
followed by radiosurgery for vestibular schwannoma
Abbreviation: F/U, follow up; FNP, facial nerve palsy; UM,
unmeasured
N 9 8 25 8
Recurrence 1 0 8 0
Recurrence rate 11% 0% 32% 0%
GTR NTR R-STR/STR R-STR+GKS
Table 6. Recurrence rate, result of SNUH (N=50)
Abbreviation: SNUH, Seoul National University Hospital; GTR,
gross-total resection; NTR, near-total resection; R-STR, 
radical subtotal resection; GKS gamma-knife surgery
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▒ 치 료
수술은구불정맥굴뒤접근법(retrosigmoid approach)를통해수
술한환자가 86%, 미로경유접근법 (translabyrinthine approach)
를통해수술한환자가12%였으며, 구불정맥굴앞및뒤접근법을함
께사용(combined pre- and retro-sigmoid approach) 하여수술
한 환자가 2%였다. 종양의 제거 정도는 완전절제(GTR)한 환자가
18%, 근전절제(near-total resection, NTR)한환자가16%, 근치적
아전절제(radical sub-total resection, R-STR)한환자가62%, 그
리고아전절제(STR)한환자가4%였다(Figure 1). 수술후추가적인
방사선수술을시행했던환자는근치적아전절제를시행하였던환
자중8명에서감마나이프수술(gamma-knife surgery)을시행하
였다.
▒ 결 과
전체재발률은 50명 중에 9명으로 18%였으며, 완전절제된환자
중 1명이재발되었고, 근전절제된환자군과근치적아전절제후감
마나이프를추가로치료했던환자군에서는재발이없었으나, 수술
후추가적인방사선수술을받지않은근치적아전절제와아전절제
환자군에서는32%에서재발하였다(표6). 
수술후안면신경보존된환자 (House-Brackmann grade 1 또
는2를보인환자)의수는50명중39명으로보존률78%을보였다.
종양의제거정도에비례하여안면신경보존률은감소하였는데, 완
전절제된환자군의경우56%, 근전절제된환자군의경우62.5%, 근
치적아전절제된환자군은87%, 그리고아전절제된환자군의경우,
수는적지만100%의안면신경보존률을나타내었다(Table 7).
▒ 결 론
크기가큰청신경초종을수술함에있어안면신경을확실하게보
존할수있는상황에서라면, 가능한근전절제를시행하는것이바람
Definition, Extent of resection of vestibular schwannoma
A. Partial resection (PR): < 50% removal
B. Subtotal resection (STR): 50-89% removal
C. Radical STR (R-STR): ≥ 90% removal with a small residual
in internal auditory canal, facial nerve, brainstem
D. Near-total resection (NTR): ≥ 95% removal with leaving only
capsule attached to internal 
E. Gross-total resection (GTR): 100% removal
A B
D E
C
Fig. 1
N 9 8 31 2
FNP 4 3 4 0
Preservation rate 56% 62.5% 87% 100%
GTR NTR R-STR STR
Table 7. Facial nerve function preservation rate*, 
result of SNUH (N=50)
* Percentage of House-Brackmann grade 1 or 2 after surgery
Abbreviation: SNUH, Seoul National University Hospital; GTR,
gross-total resection; NTR, near-total resection; R-STR, radical
subtotal resection; STR, subtotal resection; FNP, facial nerve
palsy
15크기가큰청신경초종치료의최신경향
직하며, 안면신경보존을위해일부종양을남겨근치적아전절제가
된경우에있어서는수술후남은종양에대한추가적인방사선수
술을시행하는것이종양재발을억제하는데큰도움이될것으로
보인다.
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Objective : Skull base tumors frequently encase or extend into vital neurovascular structures.
Preoperative planning and intraoperative identification of anatomic landmarks is important in
complex tumors since it helps avoid or minimize surgical morbidity. The purpose of this
study was to describe the usefulness of recent advances of neuronavigation technology in
the management of skull base tumors.
Patients and Methods : From March 2006 to May 2008, 32 patients underwent
neuronavigation-assisted surgery for skull base tumors. A Stryker Leibinger system was
used for neuronavigation. 
Results : The use of neuronavigation was beneficial both pre-and intraoperatively. Gross total
removal of the skull base tumors was accomplished in 29 out of 32 patients who were
confirmed with postoperative CT and MRI scans. All tumors were removed completely as
judged by intraoperative inspection in all patients except for three. The morbidity rates
(18.8%) were different depending on the performed surgical approaches.
Conclusions : Image guidance facilitates complex approaches to various pathologies and
enables mapping of skull base anatomy, especially during translesional dissection of
complex tumors distorting and invading the neurovascular and osseous structures.
Neuronavigation will enhance the efficacy and safety of skull base surgery. Skull base
surgery is the best target for it because of the minimum possible brain shift.
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▒ Introduction
Tumors of the skull base frequently encase or extend into
normal neural and vascular structures. Safe resection of the
skull base lesions ultimately depends on the skill and
experience of the surgeon, but evolving experience with
image guidance over the past few years indicates the
potential value of neuronavigation in skull base lesions. 4, 5, 12)
Reported benefits include optimized positioning of the
craniotomy site and the ability to define ideal vectors for
approaching deep seated intrinsic lesions with minimal
cortical trauma. The greatest value and versatility of surgical
navigation in the skull base surgery is the fact that it
provides guidance in planning the incision, determining the
size of the craniotomy flap, and assessing the extent of bone
resection at the skull base. Preoperative planning and
intraoperative localization of anatomic landmarks are
particularly important in complex skull base tumors and help
avoid or minimize the surgical morbidity.  
In this study, our preliminary experience with 35
consecutive patients operated on skull base lesions using an
advanced image guidance system is reported.
▒ Patients and Methods
From March 2006 to May 2008, 32 patients underwent
neuronavigation-assisted surgery for skull base tumors
(petroclival meningioma n=3, medial sphenoid wing
meningioma n=3, olfactory groove meningioma n=2, tentorial
meningioma n=3, foramen magnum menignioma n=1,
acoustic schwannoma n=7, trigeminal schwannoma n=4,
facial nerve schwannoma n=2, clival chordoma n=3,
suprasellar gangioglioma n=1, pituitary stalk lymphoma n=1,
brainstem hemangioblastoma n=1, and epidermoid cyst on
the cerebellopontine angle n=1). A Stryker Leibinger system
was used for neuronavigation. The decision as to which
imaging modalities and which new tools of neuronavigation
were to be applied, was guided by the approach considered,
the nature of the lesion, and the structures at risk. For
navigational planning, either computed tomography scans or
T1-weighted magnetic resonance images with 2-mm thick
axial slices with contrast injection were chosen.
Preoperatively, CT or MR scans were performed after 5-6
adhesive fiducial markers were placed in a non-colinear
fashion on the patient’s head according to the surgical
position. The CT or MR imaging data sets were transferred to
the computer workstation at the planning room via a
network. The computer reformatted the axial images into
coronal and sagittal views and three-dimensional images.
Intraoperative data for localization are acquired as one
infrared camera activate and receive the signal emitted from
reflective markers placed on a reference star array attached
to a Mayfield clamp fixed to the patient’s head. After patient
positioning and application of the Mayfield head clamp,
patient to image registration was performed using a non-
sterile handheld pointer. Various reflective marker arrays
were applied to surgical instruments so that they could be
used as active pointers during the operation. 
Middle fossa approach for the left facial schwannoma. Intraoperative
neuronavigation showing the precise localization of the tumor in the
internal acoustic meatus.
Fig. 1
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▒ Results
The use of neuronavigation was beneficial both pre-and
intraoperatively. The preoperative image preparation
procedure and surgical planning were performed by a
navigation-experienced neurosurgeon and took 10-15
minutes for data transfer and highlighting of tumors and
anatomic landmarks. The intraoperative patient-to-image
registration procedures were also performed by a navigation-
experienced neurosurgeon and required 2 to 5 minutes with 5
to 6 skin fiducial markers. No pitfalls or technical difficulties
were noted. Because of the relative immobility of the bone
structures and/or the tumor, no significant deviation from
the preoperative registration accuracy was noted at the end
of the procedures. When compared to the intraoperative bony
landmarks (for example, the clinoid processes) that were
exposed during the surgical procedures it was estimated at
<2mm in all our cases. As skull base tumors and basally
located anatomic structures do not move due to CSF loss
during dissection, a high localization accuracy of image
guidance in skull base surgery can be assumed also for
distorted vessels and neural structures. In the present study,
gross total removal of the skull base tumors was
accomplished in 29 out of 32 patients who were confirmed
with postoperative CT and MRI scans. All tumors were
removed completely as judged by intraoperative inspection in
all patients except for three; in the first two patients with
petroclival and medical sphenoid wing meningiomas, a piece
of tumor that had infiltrated the cavernous sinus was left at
the medical surface of the cavernous sinus. A third patient
had a suprasellar ganglioglioma adherent to the
hypothalamus. The morbidity rates (18.8%) were different
depending on the performed surgical approaches. 
▒ Discussion
Operative neurosurgery has recently entered an exciting
area of image-guided surgery or neuronavigation and
application of this novel technology is beginning to have a
significant impact in many ways on a variety of intracranial
procedures. Neuronavigation was the most helpful for
operations on deeply seated lesions, skull base tumors and
Retrosigmoid approach for the right epidermoid cyst. Intraoperative
neuronavigation demonstrating porus of the right internal acoustic
meatus.
Fig. 2
Petrosal approach for the right petroclival meningioma.
Neuronavigation enables precise preoperative planning for the
tumor.
Fig. 3
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lesions in brain areas with high functionality.2, 3, 11) With its
high application accuracy, the system presented in this study
provides useful feedback to the surgeon for preoperative
anatomic orientation, precise planning and stimulation of the
surgical approach, intraoperative navigation, avoidance of
vital neurovascular structures, and assessment of the extent
of possible resection. It provided anatomic structures and
identifies the possible location of residual tumor. Skull base
tumors benefit from computer-assisted neuronavigation,
particularly while planning a critical approach. 6, 8-10) This
technology can also help to identify prominent vascular and
neural structures associated with skull base, in an effect to
providing a visual warning that these structures are in the
vicinity during an aggressive tumor resection. 
The aim of this study was to evaluate the clinical accuracy,
practicality, and impact of this navigation system on skull
base procedures. Accuracy was always sufficient for image-
guided surgery of any region of the skull base, with an
average target registration error of below 1.2 mm. Although
the impact of brain shift on image guidance and the need for
intraoperative image updating is a controversial and
unresolved issue, it is well known that skull base lesions are
remarkable for the small extent of intraoperative brain shift.
This factor predicts a high degree of reliability for
neuronavigation in the treatment of skull base pathologies.1)
Preoperative changes with tumor resection, loss of CSF and
patient position can limit the surgeon’s access to the
operative field. However, brain shift is not important in skull
base tumor. Skull base surgery seems to be the ideal
subspeciality for image-guidance technology. The
tremendous advantage of neuronavigation becomes obvious
during the treatment of skull base lesions more than in any
other type of neurosurgery, because the osseous and
neurovascular structures do not move during the surgical
manipulation. 
The latest generation of neuronavigation systems has come
up with software improvements and new tools. Today,
manual segmentation processes allow us to display vessels,
nerves and tumor 2- or -dimensionally during surgery. In
general, the tumor and the nervous tissue are more precisely
visualized by MRI, whereas the bony structures (e.g, the
temporal bone, including the middle ear, cochlea and internal
auditory meatus) are better visualized by CT. Vascular
structures are also better visualized by CT angiography or
MR angiography. With appropriate preoperative image
acquisition, image preparation, registration, and
segmentation, CT and MR image fusion can be performed,
leading to enhanced visualization and augmented reality. 7)
For skull base surgery a fused image display can provide the
surgeon with more precise information on the exact
geometric relationship between the soft tissue stuctures seen
on MRI, the bony structures observed on CT, and the
vascular structures seen on CT or MR angiography. 
The early identification of distorted and/or eroded vital
neurovascular structures during the transtumoral dissection
without anatomic landmarks is the most important benefit
that is offered by neuronavigation. Therefore, we believe that
the use of neuronavigation as presented in our series might
additionally help to keep the complication rate low in patients
suffering from extensive skull base lesions. The authors
believe that careful selection of the most suitable, not
standardized, but individually tailored approach, and
knowledge about neurovascular structures will contribute to
better outcomes in skull base surgery with lower morbidity
and mortality. 
In conclusion, although brain shift occurred following
craniotomy and with brain retraction, the relative immobility
of these lesions at the skull base permitted an accurate
targeting of all lesions with an error range of 1.0-2.5 mm
throughout the entire procedure. This relatively precise
intraoperative feedback led to more accurate recognition of
tumor landmarks. It is the authors' impression that a more
aggressive resection of these lesions was achieved than could
be without the device. The application of the neuronavigation
system not only revealed benefits for operative planning,
appreciation of anatomy, lesion location and the safety of
surgery, but also greatly enhanced surgical confidence.
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Objective : The aim of this study was to investigate the precise histological characteristics of
the boundary, using surgical specimens from patients who underwent intensive resection of
“microsurgical pseudocapsule”of clinically non-functioning pituitary tumors (CNPTs).
Furthermore, we compared the remission rate of CNPTs between subjects with (Group 1)
and without (Group 2) intensive resection of microsurgical pseudocapsule in order to
correlate the histological complete resection and endocrinological remission. 
Patients and Methods : Between January 2000 and December 2007, 113 patients underwent
intensive microsurgical dissection during the transsphenoidal surgery in one hospital (Group
1). In the other hand, 24 patients underwent conventional subcapsular resection without
intentionally removing the microsurgical pseudocapsule in another hospital (Group 2).
Results : The overall surgical remission rate in Group 1 with intensive resection of
microsurgical pseudocapsule were statistically higher than the rates in Group 2 (without
intensive resection of microsurgical pseudocapsule) (p=0.032). However, there were no
statistical differences in postoperative hormonal function change between Group 1 and 2. 
Conclusions : Our results indicate that aggressive resection of psuedocapsules increases the
cure rate without aggravating pituitary function.
논문 접수일 : 2008년 5월 21일
심사 완료일 : 2008년 6월 23일
주소 : 135-720 서울시 강남구 도곡동 146-92 
연세대학교 의과대학 영동세브란스병원
신경외과
전화 : 02-2019-3391
전송 : 02-3461-9229
E-mail : jyahn@yuhs.ac
안 정 용교신저자
Pituitary tumors, Pseudocapsule, Transsphenoidal surgery, Remission.Key Words
21임상적비기능성뇌하수체종양의미세현미경적가성피막의제거
종설1 
종설2
원저1
원저2
원저3
원저4
원저5
증례1
증례2
22 JOURNAL OF KOREAN SKULL BASE SOCIETY JULY 2008 | Vol. 1 | No. 1
▒ Introduction
Although the presence of a histological pseudocapsule
around pituitary tumors was noted in the early 1900s,2) how
the pseudocapusle is formed and the histological
characteristics of the pseudocapsule have not been clarified
until now. In addition, terminology expressing the boundary
of pituitary adenomas is unclear. Some researchers reported
that pseudocapusle is originated from the condensation of the
basement membranes of compressed peritumoral cell cord.3)
On the other hand, some investigator reported that the
boundary between the adenoma and the pituitary gland
consisted of fibrous tissue originated from the normal
pituitary gland, and regarded the boundary as a
pseudocapsule. 
To describe clearly the boundary zone, we define a “true
pseudocapsule”as a definitive capsule-like structure
identifiable histologically, and a “ microsurgical
pseudocapsule”as a peritumoral structure distinguishable
intraoperatively under an operating microscope. In this
study, we studied the precise histological characteristics of
the boundary, using surgical specimens from patients who
underwent intensive resection of “ microsurgical
pseudocapsule”of clinically non-functioning pituitary tumors
(CNPTs). Furthermore, we compared the remission rate of
CNPTs between subjects with (Group 1) and without (Group 2)
intensive resection of microsurgical pseudocapsule in order to
correlate the histological complete resection and
endocrinological remission. 
▒ Patients and Methods
Between January 2000 and December 2007, 137 patients
with CNPTs underwent transsphenoidal surgery at two
different hospitals. In one hospital, 113 patients underwent
intensive microsurgical dissection during the transsphenoidal
surgery by one neurosurgeon. In the other hospital, 24
patients underwent conventional subcapsular resection
without intentionally removing the microsurgical
pseudocapsule by another one neurosurgeon. The
demographic data of the patient population was listed in
Table 1. 
The evaluation involved a complete history, physical and
neurological examination, and radiological assessment.
Neuroradiological studies included plain X-rays and magnetic
resonance imaging (MRI). The adenomas were classified
according to the Hardy radiological classification scheme.7)
Techniques in pituitary surgeries have advanced strikingly
with development of surgical techniques, instruments,
endoscopes, and intraoperative MRI. Total resection of
pituitary tumors of Hardy grades 1 to 3 has been intended.
However, it was impossible to evaluate the significance of
intensive resection of microsurgical pseudocapsule in some
cases, including those with extreme lateral extension into the
cavernous sinus, due to difficulties in achieving complete
resection. According to these criteria, 97 patients who had
prominent cavernous sinus invasion (Hardy grade IV) were
excluded from this study. 
In all cases, MRI examination was performed annually to
evaluate whether the tumor was removed completely or had
Age (year) 45.7 (range, 23-74) 48.5 (range, 36-70)
Male/female 52/61 15/9
Hardy classification
II 13 5
III 100 19
Intensive resection of microsurgical pseudocapsule
With (group 1; n=113) Without (group 2; n=24)
Table 1. Baseline characteristics of the patients and the tumors with and without intensive resection of microsurgical pseudocapsule
in clinically non-functioning pituitary tumors.
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recurred. Remission for a CNPT was defined as a lack of
evidence of tumor remnant or re-growth, as determined by
MRI examination. A combined pituitary function test was
carried out to evaluate pituitary function before surgery, one
year after surgery, and at subsequent 1.5 year intervals from
2 to 13 years postoperatively. 
Chi-square test for independence was used to determine
the statistical significance of differences in tumor sizes,
postoperative remission rate, and postoperative pituitary
function between Group 1 and Group 2. A p value <0.05 was
considered statistically significant.
▒ Results
During the surgery, microsurgical pseudocapsules were
found in 57 (50.4%) of 113 patients in Group 1. The
pseudocapsule was visualized as a well-developed capsule
entirely covering the tumor mass; a thin fibrous envelop; a
yellowish, discolored, normal gland-like thin membrane; or
thick fibrous tissue after removal of the main tumor mass.
Some pseudocapsules exhibited dense fibrosis or
calcifications. In smaller tumors, the microsurgical
pseudocapsule tended to exist more prominently in and cover
the entire mass of the tumor, and was more easily removed.
On the other hand, in larger tumors, the microsurgical
pseudocapsule tended to be discontinuous or disrupted, not
cover the entire tumor, and was more difficult to manipulate
surgically. In these situations, intraoperative frozen
histological examination was necessary to achieve complete
tumor resection. 
The pseudocapsule was removed readily along with the
main tumor mass in 31 (54.4%) patients. The remaining 26
(45.6%) patients underwent aggressive resection of the
remnant pseudocapsule, including multiple intraoperative
biopsies. Aggressive resection of the microsurgical
pseudocapsule was more often required in larger tumor than
in smaller ones. Among these 26 patients, tumor cells
infiltration was identified in the microsurgical pseudocapsule
of 12 (46.2%) patients.
The overall surgical remission rate in Group 1 with
intensive resection of microsurgical pseudocapsule were
statistically higher than the rates in Group 2 (without
intensive resection of microsurgical pseudocapsule) (p=0.032)
(Table 2). However, there were no statistical differences in
postoperative hormonal function change between Group 1
and 2 (Table 2). 
▒ Discussion
Some investigators advocated that surgical plane for
pituitary adenomas should be included the pseudocapsule
which is an accumulation of basement membrane, collagen,
fibroblasts, pericytes, and compressed capillaries. 1) On the
other hand, other investigators reported that conventional
conservative surgical methods are likely to leave tumor cells
in the pituitary gland. 8) In our prospective study, we
demonstrated the frequent infiltration of tumor cells within
the microsurgical pseudocapsule, suggesting that tumor
remnants in the microsurgical pseudocapsule could be a
source of recurrence and an obstacle to achieving complete
Overall surgical remission rate 99.1% 83.3%
Postoperative pituitary function 52/61 15/9
Normal to normal 5 (4.4%) 0 
Improved hypopituitarism 60 (53.1%) 12 (50.0%)
Persisted hypopituitarism 39 (34.5%) 9 (37.5%)
Aggravated hypopituitarism 9 (8.0%) 3 (12.5%)
Intensive resection of microsurgical pseudocapsule
With (group 1; n=113) Without (group 2; n=24)
Table 2. Postoperative remission rates and pituitary functions with and without intensive resection of mcrosurgical pseudocapsule in
clinically non-functioning pituitary tumors. 
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remission. These results indicate that intensive removal of
the pseudocapsule could provide a higher remission rate
without deteriorating pituitary function. The results of the
present study correspond with the results of earlier studies,
which have reported that intensive resection of the
microsurgical pseudocapsule is essential to achieving
histologically and surgically total resection of the pituitary
adenoma.6)
From the surgical technical standpoint, identification of a
microsurgical pseudocapsule is very important to achieve
complete tumor removal. We also found frequent infiltration
of tumor cells inside the microsurgical pseudocapsule. These
infiltrates were difficult to remove from the normal gland
surface with conventional tumor resection methods using
curettage and were instead removed with fine instruments in
a piece-by-piece fashion. From the author’s experience, the
microsurgical pseudocapsule was visualized in a variable
fashion, such as a well-developed capsule entirely covering
the entire tumor mass; a thin fibrous envelop; a yellowish,
discolored, normal gland-like thin membrane; thick fibrous
tissue; or a calcification. Careful inspection and
intraoperative tissue biopsy at the boundary of pituitary
tumors was useful for complete resection of tumors. 
The intensive resection of pituitary adenomas could be
attributed to postoperative deterioration of pituitary function.
However, Kawamata et al.5) reported that intensive resection
of pseudocapsules was advantageous in the treatment of
GH-secreting pituitary adenomas and that it did not cause
additional deterioration to pituitary function. Our results are
consistent with the reported data, suggesting that aggressive
resection of pseudocapsule does not affect pituitary function.
In conclusion, our results indicate that aggressive
resection of psuedocapsules increases the cure rate without
aggravating pituitary function.
A. Photomicrographs of the tumor specimen obtained in en bloc with distinct pseudocapsule during surgery, showing a relatively thick layer of
connective tissue as a pseudocapsule (P) at the interface between the pituitary adenoma (T) (Hematoxlyin & eosin stain, original magnification ｘ
100).
B. With higher magnification, clusters of tumor cells are identified in the pseudocapsule (Hematoxylin & eosin stain, original magnification ｘ200).
A B
Fig. 1
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Objective : Deep location, hypervascularization, involvement of cranial nerves and vessels,
and large extension within the posterior fossa are the main difficulties for surgical resection of
the jugular foramen tumors. We describe a combined transmastoid transjugular
transtubercular high cervical approach for radical resection of these tumors.
Methods : Six patients with jugular foramen tumors were surgically treated using combined
transmastoid transjugular transtubercular high cervical approach between January 2000 and
June 2008. The complex approach for total jugular foramen exposure can be simplified in a
stepwise fashion: 1) postauricular infratemporal incision; 2) retrolabyrinthine mastoidectomy; 3)
high cervical exposure; 4) Lateral suboccipital craniotomy and transtubercular exposure; 5)
removal of the internal jugular vein (IJV), jugular bulb, and sigmoid sinus; and 6) intradural
exposure.
Results : Gross total resection was achieved in 5 patients and subtotal resection in one
patient. The histologic examination of the tumors revealed as follows: schwannoma (3 cases),
meningioma (1 case), paraganglioma (1 case), and chondrosarcoma (1 case). The most
frequent complication was a new deficit of lower cranial nerves. There were no facial nerve
injury or cerebrospinal fluid leakage. 
Conclusions : The combined transmastoid transjugular transtubercular high cervical
approach described above allows for single-staged radical resection of large complex
jugular foramen tumors. This approach has the advantage of providing total exposure of the
jugular foramen with multidirectional angles of attack without facial nerve transposition.
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▒ Introduction
Jugular foramen tumors are deeply located, may be highly
vascularized, and involve important neurovascular structures
and bone at the cranial base. They are rare and most
commonly include paraganglioma, schwannomas, and
meningiomas.5) Surgical removal of these lesions remains a
challenge, in spite of new developments of cranial base
surgical techniques. Several surgical approaches have been
developed to overcome these difficulties. According to
Rhoton,7) jugular foramen approaches can be subdivided into
three main groups: a lateral group (the postauricular
transtemporal approach subdivided in infralabyrinthine,
translabyrinthine, and transcochlear approaches); a posterior
group (retrosigmoid approach and its more extensive far-
lateral and transcondylar variants); and an anterior group
(preauricular subtemporal-infratemporal approach). Two
other groups also exist but are not suitable alone for lesion
resection: the superior group (middle fossa approach); and
the inferior group (cervical approach upward to the jugular
foramen). 
The standard surgical approach is lateral, the
infratemporal transpetrosal approach.3) It permits one to gain
superior and lateral access to the jugular foramen by drilling
of the petrous bone. During this procedure, the facial nerve is
frequently transposed anteriorly for allowing the drilling of
the bone inferior to the labyrinth.2) Manipulation of the facial
nerve exposes the patient to a non-negligible risk of facial
nerve palsy. 6) To limit the risk of facial nerve palsy, some
surgeons advocate keeping the facial nerve in its bony canal
if the nerve is not infiltrate by the tumor.1) 
Total exposure of the jugular foramen can be achieved, and
multidirectional approaches can be performed, including
suprajugular (infralabyrinthine), transjugular, infrajugular
(retrosigmoid/trranscondylar) exposures.4) Both intracranial
and extracranial tumor can be removed in one-stage
procedure. Paragangliomas, schwannomas of the lower
cranial nerves, meningiomas, and chondrosarcomas at the
jugular foramen and high cervical region are accessible
through this approach. Transection of the external ear canal
and permanent rerouting of the facial nerve is not necessary. 
The complex approach for total jugular foramen exposure
can be simplified in a stepwise fashion: 1) postauricular
infratemporal incision; 2) retrolabyrinthine mastoidectomy; 3)
high cervical exposure; 4) Lateral suboccipital craniotomy
and transtubercular exposure; 5) removal of the internal
jugular vein (IJV), jugular bulb, and sigmoid sinus; and 6)
intradural exposure.
▒ Methods
Patient population
Six patients with jugular foramen tumors were surgically
treated using combined transmastoid transjugular
transtubercular high cervical approach between January
2000 and June 2008. The relevant patient demographic
characteristics, location of tumor, and surgical outcomes for
the 6 patients underwent surgery via a juxtacondylar
approach are listed in Table 1. There were 4 men and 2
women whose mean age was 42.7 years (range 27-55 years).
1 42/M IX, X, XII JF, CPA - Total Schwannoma
2 42/F X, XII JF, CPA IX Total Schwannoma
3 44/M X JF, CPA - Total Schwannoma
4 46/F IX, X, XII JF, CPA, ME - Subtotal Meningioma
5 27/M - JF, ME Total Paraganglioma
6 55/M X, XII JF, CC X Total Condrosarcoma
Patient Age(yr)/Sex Preoperative CN deficits Site of tumor New CN deficits Extent of resection Pathology
Table 1. Patient demographics, location of tumor, and surgical outcomes in 6 patients with jugular foramen tumor underwent
surgery via a combined transmastoid transjugular transtubercular high cervical approach.
CN=cranial nerve; JF=jugular foramen; CPA=cerebellopontine angle; ME=middle ear; CC=carotid canal.
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The most common symptoms at the time of presentation
included dysphonia, unsteadiness, and dysphagia. One
patient with paraganglioma was presented with pulsatile
tinnitus and hearing loss. Four patients were found to be
suffering from at least one cranial nerve deficit in the
preoperative evaluation. 
Surgical Procedure
Position of Patient and Skin Incision
After induction of general anesthesia, the patient is placed
in supine position with the head held in a Mayfield clamp and
turned 45 degree to the opposite side. The opposite jugular
vein must be free from compression. A nasogastric tube is
inserted and intraoperative monitoring of facial and lower
cranial nerves is performed. All contact areas are protected
with foam pads or water bags. The skin incision had a
question mark-shape, starting in the temporal region and
circumscribing the ear as far as the anterior border of the
sternomastoid muscle. The skin flap is elevated in two layers.
The galeal layer is undermined from the skin flap and
subsequently elevated with periosteum. The scalp is reflected
anteriorly, and the posterior auricular muscle is seen behind
the external ear canal. The posteolateral neck muscles are
reflected posteiorly to expose the body of the mastoid. 
Retrolabyrinthine Mastoidectomy
The entire body and tip of the mastoid, the spine of Henle,
the posterior point of the root of the zygoma, the
supramastoid crest, and the asterion must be exposed before
the mastoidectomy performed. The outer mastoid triangle,
which is formed by the posterior point of the root of the
zygoma, the mastoid tip, and the asterion, marks the area of
initial drilling for the mastoidectomy. The mastoid air cells
are then systematically removed by saucerization. The
sigmoid sinus and jugular bulb are completely skeletonized,
and the mastoid air cells totally removed to expose the
presigmoid dura, the superior petrosal sinus, sinodural angle,
the middle fossa dura, and the retrosigmoid dura. 
As air cells are removed from the mastoid tip region, the
digastric ridge is encountered. For a retrolabyrinthine
exposure, the bony labyrinthine must be clearly defined with
diamond burr. The facial nerve is carefully skeletonized by
using a diamond burr under contrast, copious irrigation to
prevent thermal injury. The retrofacial air cells are removed
to skeletonize the jugular bulb further. 
High Cervical Exposure
To identify the extracranial portions of the lower cranial
nerves, the internal carotid artery, and IJV, high cervical
exposure should be performed. The digastric muscle is used
as a guide for dissection of the XII and VII cranial nerves. The
T1-weighted axial 
A. and T2-weighted coronal
B. MR images showing a jugular foramen mass extending to middle ear cavity. Preoperative DSA image
C. revealing a hypervascular tumor supplied by ascending pharyngeal artery and occipital artery. Postoperative CT scan
D. demonstrating complete removal of paraganglioma.
A B C D
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XII cranial nerve crosses the external carotid artery inferior
to the digastric muscle. The accessory nerve runs laterally to
the IJV in the majority of cases. The vagus nerve run latero-
inferior to the common carotid artery. Posterior retraction of
the IJV helps expose the carotid branch of the
glossopharyngeal nerve. 
Suboccipital and Transtubercular Exposure
A lateral suboccipital craniotomy is then performed. The
sigmoid sinus and jugular bulb must be totally exposed with
rongeurs and a high-speed drill. Bone removal is next
directed superiorly toward the jugular tubercle, a rounded
prominence found at the junction of the basilar and condylar
parts of the occipital bone. The jugular tubercle should be
drilled away as much as possible. To minimize the heat injury
to lower cranial nerves, the center of the tubercle is cored out
with a high-speed diamond drill and copious irrigation,
leaving an eggshell-thin layer of bone covering the dura that
can be elevated with microdissector. The lower cranial nerves
take a hairpin bend and exit under the jugular vein and bulb.
The inferior petrosal sinus enters the anterior medial aspect
of the jugular bulb by multiple channels coursing between the
glossopharyngeal and the vagus nerve. 
Removal of Internal Jugular Vein, Jugular Bulb, and
Sigmoid Sinus
After complete exposure of the sigmoid sinus, jugular bulb,
and IJV, the internal jugular vein is ligated just inferior to the
tumor mass. The sigmoid sinus is occluded just above the
tumor mass with a suture ligature. The lateral wall of the IJV
is incised and removed with the tumor up to the jugular bulb
and sigmoid sinus. The plane of dissection between the tumor
and the medial wall of the jugular bulb is preserved. 
Retrosigmoid Intradural Exposure
The dura mater is incised in the medial wall of sigmoid
sinus. Minimal cerebellar retraction is needed to open the
cerebellopontine cistern, exposing the intradural jugular
foramen region. Sharp arachnoid dissection is performed,
and the following structures can be visualized: Vth through
XIIth cranial nerves, basilar artery, vertebral artery,
posterior inferior cerebellar artery, and anterior inferior
cerebellar artery. 
Closure
After adequate hemostasis, the wound is irrigated with
antibiotic saline solution. Cranial base reconstruction and
prevention of a cerebrospinal fluid leak is paramount to the
success of surgery. A watertight dural closure should be the
goal. If there is a large defect, an autologous fascial graft or
pericranial flap followed by fibrin glue may be used.
Autologous fat is used to pack the mastoid defect and
remaining anatomic dead space. Temporary lumbar drainage
can be used to facilitate healing of the dural closure. 
▒ Results
The location and the extent of the lesions were determined
A. Intraoperative photograph (right-sided approach) demonstrating a glomus jugular tumor after retrolabyrinthine mastoidectomy and skeletonization
of sigmoid sinus.
B. Extradural reduction of jugular tubercle is the key maneuver in this approach. The jugular tubercle should be drilled away as much as possible. 
C. The tumor is carefully removed from the pars nervosa with care taken not to damage the lower cranial nerves.
D. After complete exposure of the sigmoid sinus, jugular bulb, and internal jugular vein, the internal jugular vein and sigmoid sinus were ligated.
FN=facial nerve; IJV=internal jugular vein; SC=semicircular canal; SS=sigmoid sinus; T=tumor.
A B C D
Fig. 2
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preoperatively using the radiology reports (high resolution
computed tomography with bone windows and magnetic
resonance imaging), which was subsequently confirmed
intraoperatively. The frequency of involvement of the various
structures was as follows: jugular foramen, cerebellopontine
angle, middle ear, carotid canal. The jugular bulb was already
closed by the tumor in 3 cases. One patient underwent
preoperative embolization. 
Gross total resection was achieved in 5 patients and
subtotal resection in one patient. The histologic examination
of the tumors revealed as follows: schwannoma (3 cases),
meningioma (1 case), paraganglioma (1 case), and
chondrosarcoma (1 case). Meningioma showed no clear
cleavage plans and total removal is not possible. 
The most frequent complication was a new deficit of lower
cranial nerves. Two patients developed lower cranial nerve
palsy temporarily. There were no facial nerve injury or
cerebrospinal fluid leakage. Postoperative radiosurgery was
performed in one patient with meningioma. 
▒ Discussion
The combined transmastoid transjugular transtubercular
high cervical approach described above allows for single-
staged radical resection of large complex jugular foramen
tumors. This approach has the advantage of providing total
exposure of the jugular foramen with multidirectional angles
of attack without facial nerve transposition. 
In our experiences, the expanding tumors, such as
schwannomas or chondrosarcomas, are fairly easy to remove
and can be done without facial nerve transposition. However,
facial nerve transposition may be needed in surgery for
infiltrative tumors such as meningiomas or malignant
tumors. 
In anatomic study of the jugular foramen, cranial nerve,
jugular bulb, and IJV are surrounded by a single connective
tissue sheath.8) Therefore, jugular bulb and internal jugular
vein can be separated from internal carotid artery and cranial
nerves by microsurgical techniques. Dissection of dense
connective tissue around the IJV is important for wide
exposure of jugular foramen with gentle retraction of IJV
instead of facial nerve transposition. 
The multidisciplinary approach gives the best chance of
radical removal with preservation of cranial nerves and
vessels. To avoid postoperative complications, an adequate
surgical exposure and reconstruction of the cranial base are
required. Surgical morbidity and mortality are usually
associated with damage to the lower cranial nerves.
Identification and dissection in the neck and at the foramen
magnum is helpful in the preservation of these nerves. When
they are infiltrated yet still functioning, our strategy is to
leave a small piece of tumor around them and if necessary (if
there is proven postoperative residual tumor growth)
administer radiotherapy.5)
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Treatment of cavernous sinus meningioma: 
long-term outcome and lessons learned
J Korean Skull Base Society 1 : 31~37, 2008 
OBJECTIVE : We retrospectively analyzed the long-term outcomes in patients with cavernous
sinus meningiomas (CSMNGs) treated with the various treatment modalities including surgical
resection, radiotherapy, radiosurgery, and clinical observation to find out an optimal strategy
in selecting a treatment option. 
PATIENTS AND METHOD : Of the 77 consecutive patients with CSMNGs treated between
1986 and 2004, 60 were followed up for more than 36 months. Thirty-six (60.0%) patients
were female. The mean age of the patients was 52±12 years, and the mean follow-up
duration was 83±46 months. The population was divided into four groups including the
microsurgery group (n=26, 43.3%), the observation group (n=11, 18.3%), the conventional
radiotherapy (CRT) group (n=10, 16.7%), and the radiosurgery group (n=13, 21.7%)  according
to the initial treatment modality. 
RESULTS : The actuarial tumor control rates were 84.9%, 78.3%, and 41.8% at 5, 10, and 15
years, respectively.  Adjuvant radiation therapy using (CRT) after surgery seemed to be
positively associated with tumor control, however it did not reach the statistical significance
(p=0.277). The patients treated with CRT or radiosurgery as an initial management also
showed better outcome in terms of tumor control, however which was not statistically
significant (p=0.138). Tumor progression was observed in 12 patients; 7 (26.9%) of the surgery
group, 3 (27.3%) of the observation group, 1 (11.1%) of the CRT group, and 1 (7.7%) of the
radiosurgery group. Unfavorable KPS was identified in a total of 13 patients; 7 (26.9%) of the
surgery group, 1 (9.1%) of the observation group, 4 (44.4%) of the CRT group, and 1 (7.7%) of
the radiosurgery group. Finally, aggravation of the cranial neuropathy mostly developed in 8
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▒ 서 론
두개내뇌수막종은일차성뇌종양의약30% 정도를차지하는흔
한종양이다.2) 이들의치료목표는종양의기원이되는경막을포함
한종양의완전절제이나위치에따라서완전절제가어려워수술만
으로완치되기어려운경우가많다. 해면정맥동에기원하는수막종
의경우, 수술중내경동맥의손상내지는폐색의위험과근처뇌신
경들의손상에의한수술후신경학적증상악화의가능성이매우
높아근치적수술이어렵다. 방사선치료의경우에도충분한방사선
량이조사되지못했을경우종양의성장을막지못하는경우가보고
되고있으며, 방사선에의한주변신경및혈관의손상가능성도있
어난점이있다. 해면정맥동에서기원하는수막종의적합한치료에
대해아직뚜렷한결론은 없는상태이며, 큰 규모의 연구들에서도
논란이 많다. 일부에서는 적극적인 수술적 제거를 주장하고 있으
며,1, 3-5) 정위적방사선치료를지지하는그룹도있고,7-9, 15) 적절한수
준의수술적제거후추가적인정위적방사선치료를선호하는그룹
도있다.10-14)
본 연구에서는해면정맥동을침범하는뇌수막종환자의다양한
치료경험을후향적으로분석하여각치료방법에따른장기간추
적관찰결과를평가하고, 가장적절한치료방법을모색해보고자
한다.
▒ 대상 및 방법
1986년부터2004년까지서울대병원에서치료받은해면정맥동을
침범하는뇌수막종환자77명중 36개월이상추적관찰이가능하였
던환자를대상으로하였다. 총 60명의환자가이연구에포함되었
으며, 환자를치료방법에의거하여총4개의군(수술을시행한군,
방사선치료를시행받은군, 정위적방사선수술을시행받은군, 경
과 관찰 군)으로 구분하였다. 정위적 방사선 수술에는 감마나이프
수술이 이용되었다. 각 군의 무진행 생존기간 (progression free
survival), 재발률 (recurrence rate), 치료전후의뇌신경장애정
도및Karnofsky Performance Score (KPS) 전후비교를통해치
료 성적을 비교하였다. 무진행 생존기간은 Kaplan-Meier 방법을
통해산출하였고, 재발률과KPS, 뇌신경증상변화에영향을주는
요인들을 콕스 비례위험모형 (Cox proportional hazards model)
및 이분형 로지스틱 회귀분석법 (Binary logistic regression
analysis)을이용하여비교분석하였다.
▒ 환자의 분포 및 특성
환자들의성별은남자가 24명, 여자가 36명이었고, 평균연령은
52세(15-73세)이었으며, 평균 추적관찰 기간은 83개월(36-269)이
었다. 이환자들의주증상으로는시력, 시야장애가 17명(28.3%)로
(30.8%) patients of the surgery group. Failure of tumor control was negatively related with the
outcome of the functional status and the cranial neuropathy after long-term follow-up period.  
Conclusion : Considering a high rate of tumor progression after long-term follow-up period,
CRT and radiosurgery seem to be optimal. However, in terms of the functional status and
cranial neuropathy, observation also seems to be an effective modality. Based on our
experience, selection of a treatment among various modalities for patients with CSMNGs
should be done considering the age of patient, the presence of cranial neuropathy, and the
tumor size.
cavernous sinus, meningioma, multimodal treatment, long-term outcomeKey Words
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가장 많았으며, 안면부위 감각이상이 6명(10%), 안검하수가 6명
(10%), 반마비및보행실조가5명(8.3%), 발작(seizure)을보인환자
가 5명(8.3%), 복시를 보인환자가 4명(6.7%), 두통, 어지러움증을
보인 환자가 8명(13.3%), 기타 다른 원인으로 발견된 환자가 9명
(15%)였다(Table 1).
총26명(43.3%)의환자가수술적치료를시행받았으며, 이중수
술적치료만받은환자는14명(23.3%), 수술후방사선치료를받은
환자가7명(11.7%), 수술후감마나이프수술을시행받은환자가5명
(8.3%)이었고, 방사선치료만시행받은환자가10명(16.7%), 감마나
이프수술만시행받은환자가 13명(21.7%), 경과관찰만시행한환
자가11명(18.3%)였다(Table 2). 경과관찰한그룹의평균연령이62
세로가장많았으며, 종양의평균크기는감마나이프수술을시행받
은그룹에서28mm로가장작았다(Table 3). 종양의인근구조물로
의침습정도를평가하기위해Sekhar가제시한분류를이용하였으
며, 1단계 (grade I)은 해면정맥동의 일부만 침습한 경우, 2단계
(grade II)는 해면정맥동의여러부분을침습하면서내경동맥을한
쪽으로 밀거나 일부 감싸는 경우, 3단계 (grade III)는 내경동맥을
완전히감싸는경우, 4단계(grade IV)는내경동맥을감싸면서동맥
의협착소견까지보이는경우, 5단계(grade V)는양측해면정맥동
을침습하는경우로분류하였다. 비교적수술적치료를받았던환자
군에낮은Sekhar 단계의환자비율이비교적높았고, 방사선치료
만을시행받은그룹과경과관찰을하였던그룹에높은Sekhar 단
계의환자들이속하였다. 경과관찰군에서뇌신경장애증상의빈도
가낮았다.
▒ 결 과
전체해면정맥동을침습하는수막종의무진행생존기간은중앙값
이 168개월 (95% 신뢰구간 134.6-202.4개월), 평균이 169.6개월
(95% 신뢰구간 134.1-205.1개월) 이었다 (Fig. 1). 5년무진행생존
Visual disturbance 17 (28.3%)
Trigeminal symptoms 6 (10.0%)
Ptosis 6 (10.0%)
Hemiparesis or Ataxia 5 (8.3%)
Seizure 5 (8.3%)
Diplopia 4 (6.7%)
Dizziness or Headache 8 (13.3%)
Others* 9 (15.0%)
Symptoms No. Cases
Table 1. Presenting symptoms at the time of diagnosis of
cavernous sinus meningioma
* 6 incidentally found + 2 exophthalmos + 1 hearing difficulty
Surgery only* 14 (23.3%)
Surgery + radiotherapy 7 (11.7%)
Surgery + GKRS 5 (8.3%)
Radiotherapy only 10 (16.7%)
GKRS only 13 (21.7%)
Observation 11 (18.3%)
Management No. cases
Table 2. Initial management of patients
* Gross-total resection in 4 cases
Abbreviation: GKRS, gamma-knife radiosurgery
Mean age (yr) 47±13 62±8 50±6 50±11
Mean size (mm) 41±13 37±9 44±10 28±6
Mean F/U (mo) 97±48 80±71 63±25 74±14
Preop CN deficit 16 (61.5%) 3 (27.3%) 9 (90.0%) 9 (69.2%)
Sekhar (1996) Grade I 5 1 0 4
Grade II 8 1 0 3
Grade III 9 4 3 3
Grade IV 4 4 3 2
Grade V 0 1 4 1
WHO grade Grade I 23 3*
Grade II 2
Grade III 1
Surgery Observation Radiotherapy GKRS
Table 3. Characteristics of the groups divided according to the initial management
* Surgery was carried out due to tumor progression afterwards.
Abbreviation: yr, years; mo, months; F/U, follow-up; GKRS gamma-knife radiosurgery; Preop CN, preoperative cranial nerve
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률은84.9%, 10년무진행생존률은78.3% 그리고15년무진행생존
률은41.8%였다.
수술을시행하였던그룹중수술후방사선치료를추가로시행하
였던군과그렇지않은군을비교하였을때, 통계적으로유의하지는
않으나(p=0.277) 수술후방사선치료를추가로시행하였던그룹에
서더나은종양억제율을보였다 (Fig. 2A). 방사선치료를시행한
Recurrence 7 (26.9) 3 (27.3) 1 (11.1) 1 (7.7)
Unfavorable KPS* 7 (26.9) 1 (9.1) 4 (44.4) 1 (7.7)
CN function Aggravation 8 (30.8) 1 (9.1) 1 (11.1) 1 (7.7)
Improvement 8 (30.8) 2 (18.2) 4 (44.4) 6 (46.2)
Stationary 10 (38.5) 8 (72.7) 4 (44.4) 6 (46.2)
Other Cx 4† 1‡ 3§ 1‖
Surgery(N=26) Observation (N=11) RTx(N=10) GKRS(N=13) 
No of pt (%) No of pt (%) No of pt (%) No of pt (%)
Table 4. Clinical outcomes according to the initial management
* In case of the KPS assessment worsened
† Two cases with cognitive dysfunction after RTx; one case of panhypopituitarism after RTx; one case with 2nd radiation-induced tumor   
(olfactory neuroblastoma)
‡ One hydrocephalus treated with ventriculoperitoneal shunt
§Two cognitive dysfunction; one panhypopituitarism
‖ One radiation-induced peritumoral edema treated with steroid
Gender 0.857 0.794
Age (>50 years) 1.070 0.908
F/U duration 0.976 0.054 0.975 0.031 0.952-0.998
Preoperative CN dysfunction 1.572 0.500
Sx duration (>12 months) 0.761 0.678
Size (>30mm) 1.996 0.374
Size (>40mm) 1.862 0.304
Sekhar grade 4/5 1.334 0.749
Initial radiation treatment 0.399 0.151 0.280 0.050 0.078-1.000
Univariate Multivariate
HR P-value HR P-value 95% CI
Table 5. The results of the statisticalanalysis regarding tumor progression
Abbreviation: HR, hazard ratio; CI, confidence interval; F/U, follow-up; CN, cranial nerve; Sx, symptom
Gender 2.059 0.255
Age (>50 years) 0.550 0.372
F/U duration 0.998 0.803
Preoperative CN dysfunction 1.007 0.991
Sx duration (>12 months) 1.304 0.734
Size (>30mm) 0.147 0.077 0.159 0.140 0.014-1.827
Recurrence 0.171 0.012 0.137 0.025 0.024-0.778
Sekhar grade 4/5 1.471 0.749
Initial treatment modality Observation 3.684 0.252
Radiotherapy 0.553 0.448
GKRS 4.421 0.189 1.070 0.960 0.077-14.88
Usage of radiotherapy 0.214 0.020 0.506 0.486 0.075-3.437
Univariate Multivariate
OR P-value OR P-value 95% CI
Table 6. The results of the statistical analysis regarding the functional status using KPS
Abbreviation: OR, odd ratio; CI, confidence interval; F/U, follow-up; CN, cranial nerve; Sx, symptom; GKRS, gamma-knife radiosurgery
35해면정맥동을침범하는뇌수막종의치료
그룹과그렇지않은그룹을비교하였을때, 역시통계적으로유의하
지는않으나 (p=0.138) 방사선치료를시행한그룹이더나은종양
억제율을보였다(Fig. 2B).
각치료그룹간의재발률(recurrence rate), KPS 변화, 뇌신경장
애악화정도는표4에정리하였다. 특이할사항은위에서언급한대
로수술적치료군과경과관찰군의경우재발률이높았으며, 수술적
치료군에서뇌신경장애정도가악화되는비율이높았고, 방사선치
료군의경우인지기능장애를포함한전반적인삶의질저하가다른
군에비해두드러졌다. 
재발률의다변량콕스비례위험모형을이용한분석을시행하였을
때, 초기방사선치료가재발억제와연관이있으며, 추적관찰기간
과재발률이긍정의상관관계를갖는다(Table 5). 종양의크기와재
발유무가삶의질감소(KPS의감소)에영향을주는것을나타났으
며 (Table 6), 뇌신경장애증상의악화에재발유무만이통계적으로
유의한영향을주는것으로나타났다(Table 7).
▒ 고 찰
해면정맥동을 침범한 수막종의 치료 성적을 후향적으로 분석한
이연구를통해몇가지사실을정리해볼수있다. 해면정맥동을침
범하는뇌수막종의경우, 상당한치료기술및방법의발전에도불
구하고, 장기간추적관찰시, 재발하는경우가많다. 이는종양의위
치가해부학적으로복잡하고, 시신경, 경동맥을포함하는중요구조
물들과닿아있어수술및방사선치료에제약이있어완전히종양을
근절하지못하기때문으로생각된다. 유의한종양성장억제효과는
방사선치료에서만보였다는점도주목할부분이다. 방사선치료가
어떤방식으로든치료계획에포함되어야함을의미한다.
뇌신경장애를포함, 별다른 증상이없는고령의환자들을경과
관찰하였을때, 증상의진행이없고KPS 악화비율이수술을포함
한다각적치료를시도하였던군들에비해낮은사실역시주목할
만하다. 이러한사실을근거로노인환자에서뇌신경장애증상이
Fig. 1
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The median overall progression-free survival of meningioma
involving cavernous sinus was 168 months (95% CI, 134.6-201.4).
The actuarial progression-free survival rates were 84.9%, 78.3%,
and 41.85 at 5, 10, and 15 years, respectively.
Gender 1.316 0.683
Age (>50 years) 1.895 0.342
F/U duration 0.997 0.635
Preoperative CN dysfunction 0.296 0.144 0.274 0.221 0.034-2.178
Sx duration (>12 months) 0.913 0.901
Size (>30 mm) 0.458 0.352
Size (>40 mm) 0.368 0.141 0.573 0.562 0.087-3.769
Recurrence 0.065 p<0.001 0.071 0.003 0.012-0.419
Sekhar grade 4/5 1.471 0.749
Initial treatment modality Observation 4.444 0.187 7.579 0.157 0.459-125.1
Radiotherapy 4.000 0.223
GKRS 5.333 0.136 3.425 0.365 0.239-49.10
Initial radiation treatment 1.208 0.778
Univariate Multivariate
OR P-value OR P-value 95% CI
Table 7. The results of the statistical analysis regarding the favorable outcome of cranial neuropathy
Abbreviation: OR, odd ratio; CI, confidence interval; F/U, follow-up; CN, cranial nerve; Sx, symptom; GKRS, gamma-knife radiosurgery
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없는경우, 경과관찰하는것도하나의치료전략이될수있으리라
생각된다.
종양의 성공적인 성장 억제를 위해서는 감마나이프를 포함하는
방사선수술또는방사선치료를통한적극적인치료계획이필요할
것으로보인다. 다만, 뇌의상당한영역에방사선을조사하는치료
는장기간경과관찰을하였을때, 인지기능장애, 호르몬장애, 방
사선에의한종양발현등의합병증발생가능성이비교적높으므
로, 해면정맥동을침범하는작은크기의수막종의치료는감마나이
프와같은방사선 수술이적합할것으로생각된다. 감마나이프 등
방사선수술의경우효과적으로치료가능한종양크기정도에제한
이있고, 주변에시신경등방사선에취약한중요구조물들이있는
것을감안하면, 크기가큰종양을치료함에있어서는, 수술을통한
종양크기를줄이고, 남은종양에대해서감마나이프를시행하는것
이보다효과적인치료라생각된다.
그림3에해면정맥동을침범하는수막종의저자들이제안하는효
과적인치료알고리즘을도시하였다. 진단당시종양의크기가3cm
이하일 경우바로감마나이프수술을고려하고, 만약 3cm 이상일
경우환자의나이를고려하여, 60세 이하의젊은나이의경우에는
수술을통해제거할수있는종양을최대한제거하여크기를줄인
다음, 남은 종양에 대한감마나이프 수술을시행하는방법을택한
다. 만약 60세이상의고령이고뇌신경장애의증상이없는경우에
는그냥경과관찰해볼수있으나, 뇌신경장애가있거나종양이진
행하여증상이악화되는경우에는수술후감마나이프또는내과적
Fig. 3
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The radiation treatment group versus the group without radiation
treatment. The actuarial progression-free survival rates were 77.0%
and 69.3% at 5, and 10 years respectively in the group without
radiation treatment. And the actuarial progression-free survival rates
were 90.0% and 85.3% at 5, and 10 years respectively in the patients
treated with radiation treatment using conventional radiotherapy or
radiosurgery. However, difference in tumor control between two
groups did not reach the statistical significance (p=0.138).
The surgery only group versus the surgery plus adjuvant treatment
group. The actuarial progression-free survival rates were 70.7% and
61.9% at 5, and 10 years respectively in the surgery only group. And
the actuarial progression-free survival rates were 90.0% and 80.0%
at 5, and 10 years respectively in the patients treated with surgery
plus adjuvant therapy using conventional radiotherapy or
radiosurgery. However, difference in tumor control between two
groups did not reach the statistical significance (p=0.277).
Our suggestion for management of patients with  cavernous sinus
meningiomas.
Comparison of tumor control between the groups using the  log rank test
37해면정맥동을침범하는뇌수막종의치료
문제 등으로 전신마취를통한수술이어려울 경우, 방사선 치료를
고려한다.
▒ 결 론
해면정맥동을침범하는뇌수막종은해부학적위치, 주변뇌신경
및혈관들간의관계로수술을통한완전제거가어려우며, 이를시
도하였을때, 상당한합병증및위험이뒤따른다. 낮은합병증이환
률, 장기간의종양억제를위해서는감마나이프등의방사선치료가
효과적이며, 종양의크기가큰경우수술을통해크기를줄인이후
에감마나이프를시행하는것이좋다. 고령이고뇌신경장애증상이
없는큰종양의경우, 악화없이안정적인경우가많으므로, 경과관
찰이추천된다.
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Objective : In various skull base approaches, the risk of cerebrospinal fluid (CSF) leakage
exists and the leakage may lead to a life-threatening condition such as meningoencephalitis.
The incidence of its occurrence varies in previous literatures and the management dealing
the leakage was not established. In this study, we reviewed our experiences dealing CSF
leakage after a skull base surgery and suggest a guideline of managing CSF leakage.
Patients and Methods : From 2001 to 2007, 273 patients who underwent skull base surgery
for managing tumor were reviewed retrospectively. The charts were analyzed for the date of
surgery, age and sex of the patient, the presence or absence of CSF leak, and when
present, its managements. 
Results : Among the 273 patients, six patients had CSF leakage after surgery. The incidence
of CSF leakage in this series was 2.19%. The risk of CSF leakage was highest in the
retrosigmoid and combined approaches (3.03%). Two of these patients with CSF leakage
developed bacterial meningitis, and these two patients with meningitis were treated with
intravenous antibiotics. Among the six patients, the CSF leakage had improved without a
direct surgical repair of dural defect in four patients; the others underwent a surgical repair. 
Conclusions : Our results indicate that postoperative CSF leakage can be managed activity
restriction, and lumbar-subarachnoid drainage, but in case of refractory leakage, wound
revision and surgical dural defect repair enables the patients to reduce hospital days and
further complications. 
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▒ Introduction
In surgeries approaching to the skull base including the
transoral, subfrontal, pterional transsylvian, subtemporal,
petrosal, transtentorial occipital, retrosigmoid and midline
suboccipital approach, the risk of cerebrospinal fluid (CSF)
leakage exists and the leakage may lead to a life-threatening
condition such as meningoencephalitis. The incidence of its
occurrence varies in previous literatures and the
management dealing the leakage was not established. In this
study, we reviewed our experiences dealing CSF leakage after
a skull base surgery and suggest a guideline of managing
CSF leakage.
▒ Patients and Methods
From 2001 to 2007, 273 patients who underwent skull base
surgery for managing tumor were reviewed retrospectively.
The charts were analyzed for the date of surgery, age and sex
of the patient, the presence or absence of CSF leak, and when
present, its managements. 
We diagnosed CSF leakage clinically. A CSF rhinorrhea was
diagnosed when an intermittent, clear nasal discharge
occurred on straining, leaning forward, or lowering of head.
A wound CSF collection was diagnosed when fluid with a
similar character was seen exuding through the wound of the
operation or palpable fluid collection beneath the wound. All
patients with CSF leakage had lumbar-subarachnoid
drainage and activity restriction initially. If the CSF leakage
stopped after lumbar-subarachnoid drainage,
lumboperitoneal shunt or ventriculoperitoneal shunt was
performed. And if CSF leakage continued, direct surgical
repair for dural defect was performed (Fig. 1).
▒ Results
From January 2001 to December 2007, 273 patients
underwent skull base surgeries at department of
neurosurgery in out institution. There were 116 male and 157
female patients. The mean age was 45 years (range 2-78).
The surgical approach included the subfrontal, pterional
transsylvian, transpetrosal, transcondylar, transtentorial
occipital, retrosigmoid and midline suboccipital approach
(Table 1). Among the 273 patients, six patients had CSF
leakage after surgery. The clinical characteristics of these
patients were listed at Table 2. The incidence of CSF leakage
in this series was 2.19%. The risk of CSF leakage was highest
in the retrosigmoid and combined approaches (3.03%). Two of
these patients with CSF leakage developed bacterial
meningitis, and these two patients with meningitis were
treated with intravenous antibiotics. Among the six patients,
the CSF leakage had improved without a direct surgical
repair of dural defect in four patients; the others underwent a
surgical repair. 
Fig. 1
Wound Collection
Direct repair LP or VP shunt
Compressive Dressing
Re-suture
LSAD for 7 days
Activity Restriction
Rhinorrhea
ImproveNo improve
Pterional 71 2
Retrosigmoid 66 2
Subfrontal 46 1
Transpetrosal 28 1
Transcondylar 23 0
Midline suboccipital 19 0
Occipital transtentorial 7 0
Other 13 0
Approach n CSF leakage
Table 1. Surgical approaches to skull base and cerebrospinal
fluid leakage (n=273)
The management flow chart of cerebrospinal fluid leakage after
skull base surgery. LSAD: Lumbar-subarachnoid drainage, LP:
Lumboperitoneal, VP: Ventriculoperitoneal.
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▒ Illustrative cases
Patient 1
(Fig.2. A-D) A 32-year-old male patient admitted to our
hospital suffered from dizziness and diplopia. He had
diagnosis of chordoma of clivus 5 years ago and took a tumor
removal with transoral approach. The MRI scan
demonstrated recurrence of tumor, and he underwent
surgical removal of tumor with combined far lateral and
posterior petrosal approach. The pathology was chordoma.
After the operation, the wound was swollen and he had
headache. Postoperative MRI scan and CT scan revealed mild
CSF collection and hydrocephalus. After repeated lumbar-
subarachnoid drainage, the CSF collection was improved but
hydrocephalus was still last. So, he underwent ventriculo-
peritoneal shunt and no more hydrocephalus and CSF
leakage happened. 
Patient 2
A 34-year-old male patient admitted to our hospital for
headache. The MRI scan revealed a huge tumor around the
clivus and cavernous sinus, and he underwent surgical
removal of tumor with pterional intradural and extradural
approach. The pathology was chordoma. Three days after
1 M/32 Chordoma Clivus Combined far lateral Wound collection VP shunt after LSAD No further leakage
and posterior petrosal
2 M/48 Meningioma Sphenoid wing Pterional transsylvian Rhinorrhea LP shunt after LSAD No further leakage
3 M/34 Chordoma Clivus pterional intradural Rhinorrhea VP shunt after LSAD No further leakage
and extradural
4 M/39 Meningioma Olfactory groove Subfrontal Rhinorrhea Meningitis LSAD Need direct repair
5 F/54 Schwannoma Cerebellopontine  Retrosigmoid Wound collection Aspiration No further leakage
angle suboccipital VP shunt after LSAD
6 F/54 Schwannoma Cerebellopontine  Retrosigmoid Wound collection Aspiration LSAD Need direct repair
angle suboccipital Meningitis
Sex/ Pathology Location Surgical approach Postoperative  Initial management of Results and additional Age presentation cerebrospinal fluid leak treatments
Table 2. Clinical Chracteristics of six patients with postoperative cerebrospinal fluid leakage and their management 
LSAD : Lumbar-subarachnoid drainage ; VP shunt : ventriculoperitoneal shunt ; LP shunt : Lumboperitoneal shunt
Patient 1. Preoperative MRI
A. demonstrates a clival tumor. Postoperative MRI
B. and CT scan
C. show wound CSF collection and hydrocephalus. Final CT scan 
D. after venticulo-peritoneal shunt reveals improved hydrocephalus and no wound collection. 
A B C D
Fig. 2
41두개저외과수술에서뇌척수액비루의치료
operation, clear CSF rhinorrhea developed and the CT scan
revealed hydrocephalus. He underwent ventriculo-peritoneal
shunt surgery after repeated lumbar-subarachnoid drainage.
After shunt surgery, the CSF rhinorrhea did not happened
any more. 
▒ Discussion
There are variable approaches that enable to reach skull
base and to extirpate skull base tumors safely.7) Despite the
improvement of these approach, the risk of CSF leakage after
surgery is still as high as 20%.10) The CSF leakage can be life-
threatening, because it can bring about meningitis and
encephalitis. 
In this series of 273 patients, the incidence of CSF
leakage was 2.19% and it is highest in the retrosigmoid
approach. This result was not quite defferent from previous
reports.1-6, 9, 11, 12, 13) 
We prefer to manage wound CSF collection initiaaly with
aspiration, re-suture of skin, replacement of a compressive
dressing, activiry restriction and lumbar-subarachnoid
drainage. Leonetti et al. reported 15 patients of wound
collection and after these initial management, only two
patients underwent additional wound revision surgery.8) We
had 3 patients with wound collection, and after these initial
management, only one patient needed additional wound
revision. In three patients with CSF rhinorrhea, two patients
showed improvement of leakage after lumbar-subarachnoid
drainage, and one needed wound revision surgery. After
initial management and direct surgical repair, all patients
recovered from CSF leakage. But eventually all of these six
patients underwent CSF shunting surgery a few months or
Patient 3. Preoperative MRI scan
dedonstrates a huge clival tumor
A. Axial T2,
B. Sagittal T1 with Gadolinium enhancement
C. Postoperative CT scan shows wound CSF
collection. 
D. Late CT scan reveals hydrocephalus.
E. Final CT scan after venticulo-peritoneal
shunt reveals improved hydrocephalus and
no more wound collection.
A
D E
B C
Fig. 3
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years later due to hydrocephalus. We suggested that the
cause of delayed development of hydrocephalus was the
violations of arachnoid granulation. 
▒ Conclusions
In the surgeries approaching skull base, there is a CSF
leakage which can develop life-threatening meningitis. It can
be managed activity restriction, and lumbar-subarachnoid
drainage, but in case of refractory leakage, wound revision
and surgical dural defect repair enables the patients to reduce
hospital days and further complications. 
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전두동골절수술후에발생한점액낭종에의한안구돌출증
Exophthalmos caused by mucocele developed after surgery for
frontal sinus fracture
J Korean Skull Base Society 1 : 43~47, 2008 
Mucoceles arise from the gradual accumulation of mucus material caused by obstruction of
the sinus ostium. They may enlarge sufficiently to compress orbital or intracranial structures. 
We present a case of severe exophthalmos caused by frontal sinus mucocele developed
after operation for frontal sinus fracture. At initial operation for depressed fracture of the
anterior wall of left frontal sinus, all frontal sinus mucosa was extirpated and the space was
obliterated with bovine artificial bone. The fractured pieces of the bone were replaced and
fixed with titanium mesh and screws. The reason for the delayed development of mucocele
in this patient was the unintentionally remained sinus mucosa and blockage of the natural
drainage pathway by bone graft. Exophthalmos was relieved after surgical drainage of
mucocele, resection of mucosa as much as possible and recreation of drainage pathway by
the removal of grafted bovine bone. 
This case reminds surgeons that natural drainage pathway of sinus should be kept intact
whenever possible, otherwise a mucocele may develop even many years after operation.
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▒ Introduction
Mucoceles are the result of accumulation and retention of
mucoid material within the sinus, which follows obstruction
of the sinus ostium. 1) Accidental or iatrogenic traumatic
causes account for the majority of these cases.9) The frontal
sinus fracture is one of the most common causes of frontal
sinus mucocele. The damage of the nasofrontal duct and
drainage system can induce the mucocele. Unintentionally
remained mucosa after stripping of mucosa and obliteration
for frontal sinus fracture can cause mucocele.5)
We present a case of severe exophthalmos caused by
frontal sinus mucocele developed after operation for frontal
sinus fracture and discuss the management of frontal sinus
fracture and mucocele.
▒ Case
A 51-year-old man visited the hospital with a complaint of
progressive protrusion of his left eye for 3 years (Fig. 1). 
Eight years ago he fell down stairs and suffered from a
depressed fracture of anterior wall of left frontal sinus.
Computed tomographic (CT) scan at that time disclosed
multiple comminuted depressed fracture of the anterior wall
of frontal sinus (Fig. 2). Through a coronal incision all frontal
sinus mucosa was extirpated and the space was obliterated
with bovine artificial bone (Lubbock Co). The fractured pieces
of the bone were replaced and fixed with titanium mesh and
screws. 
His left eye started protruding progressively 6 years after
the operation. He did not complain diplopia though the
proptosis of left eye was severe and vertical dystopia was
noted on examination.
Magnetic resonance imaging (MRI) demonstrated a round
cystic mass occupying the left frontal sinus and left orbit
causing proptosis, measuring 3.7 cm x 2.4 cm x 3.6 cm, with
high signal intensity on T1WI and iso signal on T2WI (Fig. 3).
Facial CT displayed cystic mass in the left frontal sinus and
The axial view of the CT taken 8 years before showing multiple
comminuted depressed fracture of the anterior wall of frontal
sinus on the left side.
Fig. 2
Preoperative face photograph showing proptosis and inferior displacement of the globe on the left side.
Fig. 1
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orbit and grafted bone packed in the left frontal sinus.
Through a bicoronal approach a rectangular window, 2 ×3
cm, was made on the anterior wall of frontal sinus using a
combination of oscillating saw and osteotome. A lateral three
quarters of the left sinus was found to be completely packed
by the bovine bone grafted in the previous operation and the
medial quarter was open and covered with normal mucosa.
The grafted bovine bone was removed to reach the mucocele
which distended down to the orbit. The mucocele was opened,
and yellowish thick content was drained out with suction
(Fig. 4). Mucosa of the mucocele was removed as much as
possible. The posterior wall of frontal sinus was found to be
intact. The periorbita was intact despite absence of most part
of the orbital roof. The bone flap was fixed with plates and
screws after a free communication between mucocele and
nasal cavity. 
The proptosis improved remarkably after operation.
Postoperative MRI and CT showed that the mucocele
disappeared (Fig. 5). 
Postoperative axial CT scans demonstrating normal frontal sinus
and complete resolution of mucocele.
Fig. 5
Intraoperative photograph revealing the yellowish mucocele
after removal of the grafted bone.
Fig. 4
Preoperative T1- and T2-weighted MR images showing a round cystic mass occupying the left frontal sinus and left orbit causing
proptosis with high signal intensity on T1WI and iso signal on T2WI.
Fig. 3
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▒ Discussion
Mucoceles are the dilated mucus-filled sinus that is lined
by mucous membrane. They are most commonly found in the
frontal and ethmoidal sinuses, are infrequent in the sphenoid
sinus and occur rarely in the maxillary sinuses.6) They result
from obstruction of a sinus ostium and frequently are related
to a previous condition as chronic sinusitis, trauma, surgery
or expansible lesion. 6) With continued secretion and
accumulation of mucus, the increasing pressure causes
erosion of the bone of the sinus, and release of natural
osteolytic factors lead to the destruction of surrounding bony
structures. These allow the mucocele to expand slowly in the
path of less resistance.6, 8) This may be into the orbit, adjacent
sinuses, nasal cavity, intracranial or through the skin.
Because of this, the most common initial symptoms are those
of visual changes and headaches, while the most common
abnormal finding is proptosis.3) 
The frontal sinus fracture is one of the most common
causes of mucocele. The frontal sinus fracture can be
classified or organized in a number of ways. The fracture can
involve the anterior table, the posterior table, or both. The
nasofrontal aperture (ostium) may or may not be involved.
The fractures may be displaced or nondisplaced, and may be
simple or comminuted.7)
If the fracture causes only the severe depression of anterior
table and does not involve the nasofrontal aperture, the
common treatment is adequate exposure, anatomic reduction,
and plating. In heavily comminuted fractures, care must be
taken to be certain that no mucosa is trapped within the
fracture lines. For severe nasofrontal aperture fracture, the
sinus should almost always be obliterated with bone or fat
graft after complete removal of mucosa. If the nasofrontal
aperture fracture is relatively minor in a patient who
otherwise would not need operative intervention, it might be
safe to reimage the patient in 1 to 3 months to be certain that
the nasofrontal aperture has remained opened and the sinus
is aerated. If this was found not to be the case, then
obliteration should be performed. Some, however, advocate
reestablishing drainage into the nose, such as with the
endoscopic Lothrup procedure with stenting of the
nasofrontal aperture. 2) Management of posterior table
fractures is considerably more controversial. Some authors
recommend open exploration of essentially all posterior table
fractures. Others advocate a treatment algorithm based on
the amount of displacement coupled with knowledge about
the presence or absence of a cerebrospinal fluid leak.4) If the
posterior table is severely comminuted it is probably prudent
to “cranialize”the sinus. This involves removing the posterior
table, sealing the nasofrontal aperture, drilling out all
mucosa, placing a pericranial flap between the bone and the
brain, and allowing the brain to expand anteriorly.7)
The cause of a mucocele in this case is obliteration of sinus
which was assumed to have unintentionally remained small
piece of mucosa. Complete removal of sinus mucosa can not
guaranteed even though thorough removal of mucosa is done
because the mucosa can be left in the holes through which
vessels pass and crevices in the bone.
The definitive treatment of mucoceles is primarily surgical.
Though traditionally mucoceles were treated with open
obliterative procedure, functional endoscopic drainage and
marsupialization has become the standard and generally
uncontested treatment.2,3 Open surgery was required in this
case as the frontal sinus had been obliterated with grafted
bone.
▒ Conclusion
The operative management of frontal sinus fractures is
somewhat variable depending on the type and extent of the
fracture and possible associated injuries. This case reminds
surgeons that the extirpation of all sinus mucosa is not
always possible and natural drainage pathway of sinus
should be kept intact unless all sinus mucosa could be
removed, otherwise a mucocele may develop even many years
after operation.
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course.
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▒ Introduction
Spontaneous intracerebral hemorrhage (ICH) in
intracranial neoplasms accounts for 1.4 to 10% of ICH.1, 5, 18, 19)
Conversely, the frequency of intracranial neoplasms in
spontaneous ICH ranges from 0.8 to 7.4%. Any type of
intracranial neoplasm can cause ICH, however frequency
varies widely among tumor type. In general, fast growing,
highly vascularized neoplasms, with irregular and fragile
vascular architecture are most frequently associated with
ICH. 9) The great majority of underlying neoplasms is
malignant, and may be primary or metastatic. 14, 16, 18)
Glioblastoma predominates among primary brain tumors,
whereas metastatic tumors are mostly melanoma,
choriocarcinoma, bronchogenic, or renal cell carcinoma. 
Although rare, neoplasms can be hidden behind an ICH and
delay histological diagnosis and proper treatment. We report
an unusual presentation of glioblastoma, with repeated
intracerebral hemorrhage and discuss their peculiar clinical
characteristics and treatments from the literature review.
▒ Case Report
A 30-year-old hypertensive male presented with sudden
onset of severe headache, vomiting, and decreased level of
consciousness. The patient’s medical and surgical history was
unremarkable. A non-contrast CT scan showed hyperdense
ICH in the left thalamus with subarachnoid extension (Fig.
1A). Magnetic resonance imaging (MRI) revealed subacute
hemorrhage with profound perihematomal edema (Fig. 1B
and C). There was no definite gadolinium enhancement.
Cerebral angiography was negative for vascular
abnormalities or tumor blush. The patient underwent
conservative care for three weeks and was discharged. Three
days later, the patient complained of recurrent symptoms and
returned to the emergency room. Repeat CT showed newly-
developed ICH at the same site with intraventricular
extension (Fig. 2A). The patient became stuporous,
underwent extraventricular drainage, and was transferred to
our hospital for further evaluation and treatment. 
On arrival, the patient was lethargic but opened his eyes
transiently to voice. There was right-sided weakness
involving the face, arm and leg. Routine laboratory
investigations, including coagulation parameters and platelet
counts, were normal. He underwent conservative treatment,
A. A non-contrast CT scan showed hyperdense ICH in the left thalamus with subarachnoid extension.
B. T1-weighted axial MR image revealed subacute hemorrhage with high-signal intensity.
C. T2-weighted axial MRI showed high-signal intensity mass with perihematomal edematous change.
A B C
Fig. 1
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including CSF drainage and anti-edema therapy with
mannitol. Ten days after admission, the catheter was
removed and there were no clinical symptoms of progressive
hydrocephalus. One month later, the patient’s mental status
decreased and CT revealed increased hemorrhage with
cerebellar extension (Fig. 2B). There was also mild
enlargement of the ventricular size. Preoperative MRI
revealed heterogeneous signal mass on T2-weighted images,
which was slightly enhanced on T1-weighted images (Fig. 2C
and D). There was perihematomal depression of metabolism
on 2-fluoro-2deoxy-D-glucose positron emission
tomography (Fig. 3). A stereotactic biopsy showed reactive
gliosis and hematoma. Due to the negative result, open
biopsy was planned through occipital craniotomy. After
proper hematoma removal, a soft, reddish-gray,
hypervascular tumor was found and removed with suction
and bipolar forceps. Histopathological examination revealed
glioblastoma, intermingled with hemorrhage (Fig. 4).
Postoperative radiotherapy and concomitant temozolomide
(75 mg/㎡) chemotherapy for six weeks, with a subsequent six
courses of adjuvant temozolomide (150-200 mg/㎡)
chemotherapy for six months were performed. Final MRI
obtained at 6 months postoperation demonstrated decreased
size. Ten months postoperatively there has been no recurrent
bleeding.
▒ Discussion
Our patient presented with an unusual stroke-like onset;
the lesion should have been differentiated from vascular
lesions, including vascular anomalies and aneurysm. Patients
with brain tumor may initially present with an acute
hemorrhage that mimics a pure hemorrhagic stroke. In the
A. Second brain CT showed newly developed ICH at the same site with intraventricular extension.
B. Third brain CT scan revealed increased amount of hemorrhage with ventricular enlargement.
C. Preoperative T2-weighted axial image revealed heterogeneous signal mass.
D. Preoperative gadolinium-enhanced T1-weighted axial image showed a well-demarcated mass with strong enhancement.
A B C D
Fig. 2
There was perihematomal depression of metabolism on 2-
fluoro-2deoxy-D-glucose positron emission tomography.
Fig. 3
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case of recurrent bleeding, physicians must be able to
differentiate brain tumor and hemorrhagic stroke
immediately. Furthermore, diagnosis delay may allow further
neoplasm spread, and cause increased morbidity and
mortality. 
In addition, cerebral neoplasms with acute ICH as the
initial presentation are usually incorrectly diagnosed and
have inadequate treatment. In spontaneous intracranial
hemorrhages caused by neoplasms, the reported incidence of
ICH as the first clinical sign of neoplastic disease ranges from
9-58%. 14, 18) CT scan is not always able to clearly identify
tumor-related ICH. If patients are treated conservatively, the
correct diagnosis will be delayed or missed. In such
situations, open or stereotactic biopsy will confirm suspicious
findings, and provide information for treatment. Adjacent
tissue should routinely be histologically evaluated because
tumor tissue may be small. When only small fragments of
specimen are obtained during stereotactic biopsy, as was in
our case, it may be difficult to confirm true tumor pathology.
In recurrent bleeding of unknown origin, open biopsy is a
better choice for tissue confirmation and relief of the mass
effect. 
In the literature review, incidence of hemorrhage in
glioblastoma is significantly higher in patients under 14 years
of age or old age.8, 18) Hemorrhage is more commonly intra-
tumoral than intracerebral. Hemorrhages occurring in
glioblastoma are frequently deep into the hemisphere, basal
ganglia, or corpus callosum. In addition, although rarely
occurs in posterior fossa, tumoral hemorrhage is common.7)
In 26-58% of cases, bleeding from a tumor usually is
symptomatic and may be responsible for the first signs of a
previously unsuspected neoplasm.8, 14) Some of these patients
were difficult to suspect of brain tumor initially. 3)
Characteristic radiological findings included: a neoplastic
core; small, multifocal clots usually at the margin of the
tumor; and, surrounding, often extensive, edema. 8) The
histological features of intratumoral hemorrhage include
tumor necrosis as well as vascular changes such as vessel-
wall hyalinization, degeneration or necrosis of vessel walls,
thrombosis, and presence of many thin-walled vessels and
ruptured vessels.5)
It is important to know the best method to exclude the
possibility of brain tumor in patients who present with acute
hemorrhage. With CT, it has been reported that an irregular
shape and atypical location can hint at tumor-related ICH. A
heterogeneous appearance with solid areas of blood, multiple
hemorrhages, and a ring-shaped hemorrhage could also be
suspected. 6, 10) Enhanced peritumoral vascularization,
particularly at the margins, may account for this feature, as
well as the fact that the tumor can cause vascular erosions in
non-neoplastic tissue. 14) Also, peritumoral edema is an
important feature in the differential diagnosis, because it is
rarely seen in the acute phase of spontaneous ICH while it is
a very common feature in expanding, space-occupying
Histopathological examination (A: periphery, B: center) diagnosed glioblastoma with high degree of anaplasia, intermingled with hemorrhage.
Fig. 4
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lesions.2) The presence of a tumor should also be suspected if
ICH are found in atypical locations e.g. subcortical, close to
dural membranes, such as the falx or tentorium, close to
major cerebral veins or sinuses, or if they are calcified. 4)
Although access to MRI can be limited, it is clearly superior to
CT for work-up of patients with acute ICH.15) As in our case,
tumor-related hemorrhage was retrospectively suspected
from initial MRI study, which showed profound
perihematomal edematous change on T2-weighted images.
The mechanism of bleeding has not been defined, but
several hypotheses have been presented. Speed of tumor
growth, vascular invasion, infarction, and necrosis may all be
the contributing factors. 13) The site of fastest growth of a
neoplasm is often in the peripheral zone and brain tissue in
this area undergoes necrosis or infarction; together with the
blood supply, brain here is stretched, causing it to bleed. 11)
Vascular invasion by tumor aggregates may cause luminal
obstruction, infarction or necrosis of the tumor, and
associated hemorrhage into the neoplasm. 12) In addition,
factor associated with hemorrhage into neoplasm includes
fibrinolysis resulting from thromboplastin activity of brain
tissue. 13) Also, local suppression of the tissue factor-
dependent coagulation cascade is a contributing factor that
permits the occurrence of intratumoral hemorrhage.17)
In conclusion, our case indicates that glioblastoma should
be taken into account as a possible cause of the repeated ICH.
The repeated intracranial hemorrhages in young patients are
suspect for bleeding due to a brain tumor when there is no
evidence of other common causes such as cerebral aneurysm,
vascular malformation, or hypertensive cerebrovascular
disease. Direct proof of hemorrhagic origin is essential for
diagnosis and treatment of an ICH with atypical location,
image findings, or clinical course.
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의하단에표시한다.
2) 초록
초록은 영문으로 작성하되 200단어 이내로 연구목적, 대상 및 방법,
결과 및 결론을 간략하게 요약한 내용이 포함되어야 한다. 초록의 말
미에는 Index medicus에등재된용어로영문색인단어(key words)를
5단어이내로삽입하여야한다.
3) 서론
연구의배경과목적을 3-4문자이내로간결하게기술하되원고내용과
관련되지 않은 내용은 피하고, 본 논문의 결과나 결론을 포함하지 않
는다.
4) 대상및방법
연구대상의선택, 연구방법및통계적검증의순서로기술한다. 
5) 결과
표나 그림의 내용을 이용하여 구체적이고 논리적으로 기술하되 표나
그림의모든내용을반복해서기술하지않는다. 
6) 고찰
본 연구결과에 대한 고찰 및 직접 관련이 있는 다른 자료와의 연관점
을비교하여결과의의미와향후연구에대한영향을간결하게기술하
며, 서론이나결과의내용과중복되지않도록한다. 
7) 참고문헌
참고문헌은 본문에 나타난 것만 인용하고, 원저는 20편 이내, 증례보
고는 15편 이내로 한다(단 종설의 경우는 예외로 한다). 제1저자의 성
의알파벳순서에따라배열하며아라비아숫자로어깨번호를반괄호안
에표시한다. 동일저자의경우연도순으로나열하며, 국내문헌도영문
표기를 원칙으로 하나, 영어표기나 불가능한 경우에만 한글로 작성할
수있다. 외국논문의경우참고문헌저자는 6인까지있는경우에는모
두기재하고 7인 이상은 6인까지 기재후 et al을 붙인다. 저자표시는
투고 규정
논문의성격및게재자격I
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성의 last name을다쓰고 first name과 second name은첫글자를
대문자로붙여쓰며, 이때 initial에는 마침표 (.)를 사용하지않는다. 저
자명 사이에는 쉼표 (,)로 구분하고 마지막 저자 또는 et al 뒤에는 마
침표(.)를 찍어 제목과 구분한다. 국문논문의 경우도 동일하다. 인용논
문의 제목은 첫 글자는 대문자로 하고, 부제목이 있는 경우 쌍점 (：)
을 붙인 후 소문자로 기재하며 제목 뒤에는 마침표 (.)를 붙여준다. 잡
지 명은“List of Journals Indexed in Index Medicus”에 의거하여
약어로 기재하며 이 때 잡지 명 뒤에는 마침표(.)를 붙이지 않는다. 이
어서권수(호수) : 시작쪽-끝쪽의순으로기재한후쉼표 (,)를 찍고연
도를표시한다.
1) Auwens LJ, Veldman JE, Bouman H, Ramaekers FCS,
Huizing EH. Expression of in-termediate filaments proteins in
the adult human cochlea. Ann Otol Rhinol Laryngol 1991;
100:211-218, 1991 (저자가 6명이하인경우)
2) Raveh J, Turk JB, Ladrah K, Seiler R, Goday N, Chen J, et
al. Extended anterior subcranial approach for skull base
tumors: Long-term results. J Neurosurg 82:1002-1010, 1995
(저자가 7명이상인경우)
3) Cho YS, Hong SH, Ryu JS, Jung JY. Changes in cochlear
blood flow by anterior inferior cerebellar artery occlusion in
guinea pigs. Korean J Otolaryngol 41(2): 160-167, 1998 (국내
논문저자가6명이하인경우)
4) Traynelis VC, McCulloch TM, Hoffmann HT. Craniofacial
resection of neoplasm of anterior skull base. In: Rengachary
SS, Wilkins RH, eds. Neurosurgical Operative Atlas.
Baltimore: Williams & Wilkins:329-40, 1993 (Chapter in a
book)
6. 사진은 흑백 또는 컬러로 선명해야 하며, 컬러인쇄의 경우는 별도비
용이 저자에게 청구된다. 크기는 3×5 인치의 크기로 광택인화지를
사용하며, 사진뒷면에 그림번호, 저자의 이름, 그림의 상하를 표시해
준다. 그림설명과 도표는 영문으로 작성함을 원칙으로 하고, 표의 제
목과 그림설명은 논문을 읽지 않아도 이해할 수 있도록 상세히 기술
하여야한다.
7. 증례보고는상기원고구성규정에준하지않으며간단히기술하여내
용이 A4 용지 5매를초과하지않도록한다. 영어초록은 150 단어이
내로하며서론, 증례, 고찰의순서로기술한다. 결론또는요약은필요
한경우에만시술하고저자는4인이내만인정되며인용하는참고문헌
은 15편이내로한다.
1. 원고는 원본과 복사본 2부(사진은 원본과 동일한 것)를 작성하여 발간
2개월 전까지 아래 주소의 간행위원회로 제출한다. 연 2회(6월, 12월)
발행하므로연중원고를접수한다.
2. 논문심사료, 게재료, 인쇄제본료, 기본별책료등은학회에서부담한다.
별책부수를 논문표지에 명기하며, 별책부수를 표기하지 않은 것은 본
지관례에따른다(50부). 별책은 추후 저자에게배부하며추가별책료
는저자가출판사로지불한다.
3. 원고의 교정은 저자가 책임지며 심사 후 게제가 결정된 원고는 수정
보완된내용이수록된디스켓또는 CD 1부와수정된원고 1부를간행
위원회앞으로제출한다. 
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